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Abstract: Pulmonary infections may be fatal especially in immunocompromised patients and patients with under-
lying pulmonary dysfunction, such as those with cystic fibrosis, chronic obstructive pulmonary disorder, etc. Ac-
cording to the WHO, lower respiratory tract infections ranked first amongst the leading causes of death in 2012, 
and tuberculosis was included in the top 10 causes of death in low income countries, placing a considerable strain 
on their economies and healthcare systems. Eradication of lower respiratory infections is arduous, leading to high 
healthcare costs and requiring higher doses of antibiotics to reach optimal concentrations at the site of pulmonary 
infection for protracted periods. Hence direct inhalation to the respiratory epithelium has been investigated extensively in the past decade, 
and seems to be an attractive approach to eradicate and hence overcome this widespread problem. Moreover, engineering inhalation for-
mulations wherein the antibiotics are encapsulated within nanoscale carriers could serve to overcome many of the limitations faced by 
conventional antibiotics, like difficulty in treating intracellular pathogens such as mycobacteria spp. and salmonella spp., biofilm-
associated pathogens like Pseudomonas aeruginosa and Staphylococcus aureus, passage through the sputum associated with disorders 
like cystic fibrosis and chronic obstructive pulmonary disorder, systemic side effects following oral/parenteral delivery and inadequate 
concentrations of antibiotic at the site of infection leading to resistance. Encapsulation of antibiotics in nanocarriers may help in provid-
ing a protective environment to combat antibiotic degradation, confer controlled-release properties, hence reducing dosing frequency, and 
may increase uptake via specific and non-specific targeting modalities. Hence nanotechnology combined with direct administration to the 
airways using commercially available delivery devices, is a highly attractive formulation strategy to eradicate microorganisms from the 
lower respiratory tract, which might otherwise present opportunities for multi-drug resistance. 
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1. BACKGROUND 
 Inhalation is one of the oldest forms of medicament delivery 
dating back to the ancient Egyptian civilization where inhalation of 
vapours of black henbane were employed to help breathless patients 
breathe [1]. Currently, this complex route is used primarily for local 
treatment of respiratory diseases, such as cystic fibrosis, chronic 
obstructive pulmonary disease (COPD), bronchiectasis, asthma, 
pneumonia, aspergillosis and tuberculosis. Small molecules such as 
glucocorticoids e.g. budesonide, fluticasone, beclometasone; ?2-
adrenoceptor agonists e.g. salbutamol (albuterol), terbutaline, sal-
meterol, anti-muscarinic bronchodilators e.g. ipratropium, tiotro-
pium and antimicrobials e.g. tobramycin, aztreonam, colistin, pen-
tamidine have been, and are being successfully administered to the 
lungs for treatment of respiratory diseases. In this way, the drug 
directly reaches the desired site of action, leading to the possibility 
of dose reduction as compared to oral and parenteral routes, reduc-
ing medicament costs and also ensuring a higher concentration of 
drug is retained at the target site [2, 3]. This reduces the possible 
side effects due to decreased systemic exposure and helps in 
achievement of faster onset of action [3]. Numerous studies have 
demonstrated that antimicrobials, such as amikacin, tobramycin, 
rifampicin and amphotericin B used for treatment of lower respira-
tory tract infections caused by organisms like Pseudomonas aeru-
ginosa, Candida albicans and Mycobacterium tuberculosis have 
serious adverse effects, including ototoxicity and nephrotoxicity, 
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when administered orally or IV, which are ameliorated by a direct 
pulmonary delivery [4-8]. Due to the relatively low metabolic activ-
ity in the lung, pulmonary delivery is attractive for delivery of 
drugs which are sensitive to gastric pH, enzymes and metabolizing 
enzymes, particularly those associated with metabolism within the 
liver [9]. It is also useful for drugs belonging to Class IV of the 
Biopharmaceutics Classification System, such as amphotericin B, 
which has low water solubility and low membrane permeability, 
resulting in limited oral absorption and hence is administered rou-
tinely by the invasive IV route [10-12].  
 Effective pulmonary drug delivery requires sophisticated aero-
sol formulation approaches and complex delivery devices. Moreo-
ver, pulmonary delivery is a challenge due to the complex anatomy 
and physiology of the airways, restricting access and promoting 
clearance of inhaled materials [3].  
2. PRE-REQUISITES FOR INHALATION: FACTORS  
AFFECTING PULMONARY DRUG DEPOSITION 
 The therapeutic effect of an inhaled medicament depends 
largely on its deposition pattern and distribution in the lungs; hence, 
understanding the concepts and mechanisms of these processes is of 
fundamental importance to inhalation therapy. Deposition is a proc-
ess by which particles stick or adhere to the surface [13].  
 From a formulation viewpoint, the deposition profile is largely 
dependent on the aerosol particle characteristics, namely: aerody-
namic size, particle size distribution, shape, density, electric charge, 
hygroscopicity and stability. Other factors include lung morphol-
ogy, clearance mechanisms (mucociliary and alveolar macro-
phages), type and severity of lung disease, airflow obstruction and 
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patient factors, such as inhalation pattern, flow rate, breath-holding 
time, correct use of devices, etc.[14-15]. 
 Aerosol particle deposition in the airways is governed by three 
main mechanisms namely: Inertial impaction, gravitational sedi-
mentation and Brownian diffusion [15]. 
2.1. Inertial Impaction  
 Large particles with high momentum (i.e. product of mass and 
velocity) do not follow the lung structure with the flowing air 
stream and are deflected by the airway branching due to inertia and 
hence convective fluid motion leading to deposition on the airway 
wall [13, 15, 16]. This occurs mainly at the airway bifurcations of 
large conducting zones of airway and nose, mouth, pharynx, larynx 
and bronchial region. This is a velocity-dependent mechanism is the 
main method for deposition of particles greater than 5 ?m [17]. 
2.2. Gravitational Sedimentation  
 This results from the gravitational force acting on particles with 
sufficient mass. Deposition due to gravity increases with increasing 
particle size, density and with longer residence time, acting when 
the particle velocity is low resulting in loss of balance between the 
gravitational force and the drag force of air leading to subsequent 
deposition on the lower airway surface. Gravitation sedimentation 
is an important mechanism of deposition for particles in the range 
0.5-3 ?m in small conducting airways, like bronchioles and alveoli 
where the air flow rate is low [13, 15, 16]. 
2.3. Diffusion  
 This mechanism of deposition predominates for particles <0.5 
?m and is governed by random Brownian motion. Particles are 
displaced by random motions of air molecules, move along the 
airway streamlines, and deposit on contact with the cells by sequen-
tial bombardments. Deposition by diffusion is directly proportional 
to particle size and occurs in the alveoli and smaller respiratory 
bronchioles, where bulk airflow rate is low or absent [13, 15].  
2.4. Aerosol Characteristics  
 Aerodynamic diameter is the most important physical property 
of an aerosol that governs the proportion of the dose deposited in 
the airways and can be described as:  
dae = dg (?e / ?s ?) ? 
where, dg is the particle geometric diameter, ?e and ?s are the effec-
tive particle and unit (1g/cm3) density respectively and ? is the dy-
namic shape factor of the particle, i.e. the ratio of particle drag force 
to that of a sphere of equivalent volume and is 1 for a perfect 
sphere. Aerodynamic diameter explains the movement of aerosol 
particles in an air flow not only with respect to their geometric di-
ameter but also taking into consideration their shape and density 
[18]. 
 Surface roughness of a particle impacts the aerosolization effi-
ciency of a dry powder inhalation as it determines the interaction 
forces between the drug particles and between the drug and carrier 
particles (if present) in a formulation. An appropriate balance be-
tween the interaction forces (during mixing/filling) and separation 
forces (during inhalation) of these particles is essential to ensure 
efficient delivery of the medicament to the peripheral lung, when 
delivered as dry powder inhalations [19-21]. Studies have demon-
strated that an increase in surface roughness of lactose carrier parti-
cles and sieved sorbitol particles proportionately improves the drug 
carrying capacity of the carrier; however the drug particles are held 
tightly to the carrier particles and hence the emitted dose from the 
inhaler device decreases [19-21]. 
 Particle shape plays an important role in the aerodynamics of 
dry powders. Studies have shown that the elongation ratio and 
shape factor of a particle dictates its trajectory in the respiratory 
tract. Rod-shaped particles of carrier lactose showed an increase in 
fine particle fraction compared to approximately spherical particles, 
due to a spatial hindering effect [20, 22]. Another study performed 
on rod-shaped cromoglicic acid showed an increased fine particle 
fraction due to their shape being analogous to that of asbestos fibres 
which have a higher susceptibility for pulmonary deposition [23, 
24]. The study of the relationship between shape and surface prop-
erties is important as it can affect the aerodynamics of dry powders. 
With higher elongation ratios, the contact area between the particles 
is greater, leading to an increased cohesiveness between the parti-
cles which may ultimately affect the aerodynamic performance of 
the particles.  
 Other than size, shape and surface roughness, deposition is also 
governed by various other formulation parameters, such as hygro-
scopicity, polymorphic form, inter-particular forces and surface 
charge. 
3. PULMONARY DRUG DELIVERY DEVICES 
 Aerosols are an effective way to deliver medications to the 
pulmonary site. These are two-phased, stable dispersions or suspen-
sions of solid or liquid droplets in a gaseous phase usually air, and 
can be generated by a passive breath-driven or an active single or 
multiple dose inhaler [25]. Therapeutic aerosols can be delivered 
using three broad types of devices, namely: nebulizers, pressurized 
metered dose inhalers (pMDIs) and dry powder inhalers (DPI), 
though other delivery means have been described. The advantages 
and disadvantages of the different inhaler devices are outlined in 
Table 1. 
3.1. Nebulizers 
 These were the first devices to be used and they are still em-
ployed for pulmonary drug delivery by the pediatric and geriatric 
populations for delivering drugs such as salbutamol for pediatric 
asthma, sodium cromoglicate inflammation, tobramycin for infec-
tions associated with cystic fibrosis and COPD, corticosteroids and 
bronchodilators for severe COPD, etc. Nebulizers needs minimum 
patient skills or inhalation/actuation co-ordination [26]. Nebulizers 
deliver drug in droplets generated from solutions or suspensions. 
They have an advantage of delivering large doses during tidal 
breathing. Nebulizers can be classified as:  
Pneumatic or Jet Nebulizers  
 These operate on the Bernoulli principle by which high velocity 
compressed air passes through narrow orifice creating an area of 
low pressure at the outlet, causing the drug solution to be drawn up 
from the reservoir, forming a liquid film which breaks down into 
liquid droplets due to surface tension. Large droplets are retained in 
the device and a fine mist emitted for inhalation via a mouthpiece 
or facemask [14, 27].  
Ultrasonic Nebulizers  
 These contain a piezoelectric crystal which vibrates at a fre-
quency of 1-3MHz producing waves which are transmitted to the 
surface of a drug solution leading to formation of standing waves, 
forming a fountain of fine mist. Small droplets, having a size in-
versely proportional to the value of crystal vibrational frequency, 
are produced in the mist [14, 27, 28].  
Vibrating-Mesh Nebulizers  
 These contain a piezo-element which vibrates a perforated 
membrane in resonant bending mode. The cross-section of the per-
forations is larger at the reservoir side and narrower at the droplet 
emergence side. The size of aerosol droplets produced can be 
modulated by changing the number of perforations and their sizes 
[29]. 
 Electrohydrodynamic atomizers (EHDA): Also referred to as 
electrospraying, these produce particles suitable for deep lung de-
livery by a low-shear technique wherein application of electrical 
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forces in a controlled manner can be useful in production of mono-
dispersed droplets of size in the nanometric to micrometric range 
depending on the frequency applied during particle production [30]. 
Studies performed by Chattopadhyay et al. [31] compared the at-
omization of DPPC: DPPG: Chol liposomes using jet atomization 
and electrospraying highlighted that on atomization of lower con-
centration of liposomal suspensions (0.1 mg ml-1) using -jet atomiz-
ers only 15% of droplets contained liposomes whereas the rest was 
constituted of only buffer salt particles. However, when atomizing 
using electrospraying higher droplet lipid mass concentrations 
could be obtained [31]. 
3.2. Pressurized Metered-Dose Inhalers: pMDIs 
 These multi-dose devices have an aluminium canister equipped 
with a metering valve which contains drug dissolved or suspended 
in liquid propellant(s) along with other excipients, such as surfac-
tants, e.g. SPAN 85, oleic acid and soya lecithin and co-solvents, 
usually ethanol. Actuation of the valve leads to emission of the 
aerosol as a metered dose of drug dissolved or dispersed in propel-
lant, usually a hydrofluoroalkane [14, 27, 28, 32].  
3.3. Dry Powder Inhalers: DPIs 
 Subsequent to the development of pMDIs, dry powder inhalers 
(DPIs) were designed, and these received added interest in recent 
years as ozone-depleting chlorofluorocarbon (CFC)-based pMDIs 
have been phased out for environmental reasons. DPIs have no 
propellant and in some respects are more user friendly devices [33].  
 DPIs exist in many designs which need for their operation a 
degree of manual dexterity, although simpler DPIs are being re-
searched [34]. DPIs dispense a metered quantity of powder in an air 
stream drawn through an inlet system by the patient’s inspiration, 
directing air through the loose powder aggregates and forming a 
drug aerosol cloud. Hence, these are passive breath-actuated de-
vices [28, 35]. They are robust, portable and convenient in terms of 
formulation, processing and stability as they are a one-phase solid 
system. They do not require to be sterile and avoid the formulation 
issues of nebulizers and pMDIs, particularly for suspension formu-
lations, such as sedimentation, flocculation and foaming which may 
impact performance [36].  
 DPIs are receiving increasing interest due to drawbacks of the 
use of propellants and the requirement of inhalation-actuation syn-
chronization when using pMDIs. However, this class of devices is 
subject to strict regulatory manufacturing and pharmaceutical stan-
dards so that they are reproducible and reliable with respect to de-
livered dose uniformity [37]. This requires that a number of charac-
teristics of the DPI highlighted below should be satisfied in order to 
achieve patience adherence, device reproducibility/reliability and 
clinical efficacy.  
 The characteristics of an ideal DPI can be divided on the basis 
of:  
? Patient acceptance [37-39] 
• Simple operation. 
• Portable and easy to carry. 
• Multiple dosage reservoir. 
• Cost effective and/or reusable. 
• Dose counter, dose-ready indicator and an audiovi-
sual indicator of doses remaining. 
• Patient feedback mechanism to indicate successful 
dosage administration. 
? Device reliability and reproducibility with respect to 
dosing [37-41] 
• Consistent and homogeneous dose delivery of medi-
cament throughout the life of inhaler, at least compa-
rable to a pMDI. 
• Accurate and uniform dose delivery of medicament 
over a wide range of inspiratory flow rates with 
minimal variation with respect to age, gender and 
disease state. 
• Optimum and reproducible control on respirable 
fractions with high fraction of particles in respirable 
range for deep lung delivery. 
• Low oropharyngeal deposition with high bronchial 
deposition. 
? Efficient device [37-41] 
• Good protection from environmental moisture to 
prevent change in powder aerosol characteristics. 
• In-process quality control. 
• Minimal adhesion between the drug and inhalation 
device. 
• Device suitable for a wide range of drugs and doses 
• Environmentally accepted device. 
 No DPI can fulfil all the requirements of an ideal inhaler; how-
ever, continuous research is being conducted to improve their per-
formance to achieve optimal fine particle dosage of medicament, 
with improved patient acceptability. Patient education is of utmost 
importance with regards to use and storage of their DPI prepara-
tions. 
 Antimicrobial products for aerosol administration currently 
marketed and in clinical trials are outlined in Tables 2 and 3 respec-
tively.  
4. TYPES OF LUNG INFECTIONS 
 Indigenous populations living in affluent countries are seriously 
affected by acute and chronic respiratory diseases resulting in a 
high burden to their health [49]. These diseases can be defined as 
any infectious diseases of the upper or lower respiratory tract, 
wherein, upper respiratory tract infections (URTIs) include com-
mon cold, tonsillitis, acute rhinosinusitis and acute otitis media. 
Lower respiratory tract infections (LRTIs) include acute bronchitis, 
bronchiolitis, pneumonia and tracheitis, and are a major health issue 
in many countries [49, 50]. Bacterial, fungal and viral infections 
occur frequently and play a crucial role in progression of chronic 
pulmonary diseases, such as COPD, CB, TB and CF due to acute 
exacerbations leading to substantial long-term consequences, mor-
bidity and mortality [49, 51, 52]. 
4.1. Bacterial infections 
 Bacterial pathogens can be classified on the basis of their infec-
tion lifestyle in host and, hence can be either intracellularly or ex-
tracellularly located.  
Extracellular Pathogens  
 Most infections in CF, COPD, CB, etc., are caused by bacterial 
pathogens, such as Staphylococcus aureus, Escherichia coli and 
Pseudomonas aeruginosa. These organisms live extracellularly and 
hence are easier to eradicate than intracellular infections, which are 
present in special compartments, for instance alveolar macrophages 
and epithelial cells, where delivery of antibiotics faces greater chal-
lenges. Nevertheless, extracellular bacterial pathogens overcome 
antibiotic susceptibility by other means such as genetic modifica-
tion and production of a sessile, slimy covering called a ‘biofilm.’ 
etc. [53]. These are explained briefly in the following sections. 
 Pseudomonal infections: Psuedomonal infections are clinically 
significant and can lead to life-threatening diseases and multiple 
organ failure [54]. Pseudomonas aeruginosa is the most prevalent 
of this class of pathogens and has been long associated with a vari-
ety of clinical problems. It is an opportunistic nosocomial pathogen 
and is the major infective organism leading to high mortality and 
morbidity in hospitalized patients [54, 55]. It leads to sepsis in  
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Table 1. Advantages and disadvantages of different inhaler devices. 
INHALER 
TYPE 
 
NEBULIZER (JET, ULTRASONIC, VI-
BRATING MESH) 
 
PRESSURIZED METERED- DOSE 
INHALER (pMDI) 
 
DRY POWDER INHALER (DPI) 
ADVAN-
TAGES 
Does not require inhalation actuation synchro-
nization 
No propellant  
High doses can be delivered 
Optimal for pediatric, geriatric and diseased 
patients who cannot use other devices 
Present generation of vibrating-mesh nebuliz-
ers can be battery operated and hence portable 
(e.g: Aerogen Vibronic™) 
Portable and compact 
No preparation required 
No contamination risk 
Multidose (approx. 200 doses) 
High reproducibility between doses 
Sealed environment prevents drug deg-
radation 
Cost-effective 
Portable and compact 
Does not require inhalation actuation 
synchronization 
No propellant 
Ease in use 
Breath actuated 
No need for spacers 
DISADVAN-
TAGES 
Expensive, wasteful 
Contamination risk 
Time consuming 
Different models and operating conditions lead 
to high performance variability 
Drug formulation preparation may be neces-
sary 
Nebulizer performance may decline over time 
Requires inhalation-actuation synchroni-
zation 
High oropharyngeal deposition observed 
Maximum dosage that can be adminis-
tered is approximately 5 mg 
Young children require valved-holding 
chamber (spacer) 
Propellant- based 
Respirable dose dependent on inspiratory 
flow rate, tidal volume, breathes/cycle 
etc. 
Respirable dose dependent on the dry 
powder particle properties 
Moisture/electrostatic attraction may lead 
to powder aggregation, changing aerody-
namic properties and/or causing capsule 
softening 
 
Table 2. Approved anti-microbial aerosols preparations [42-46]. 
FORMULATION NAME ANTIMICROBIAL DEVICE AND DOSE ADVANTAGES INDICATIONS 
TOBI®- Tobramycin inhalation 
solution USP (TIS) 
Novartis 
Tobramycin 
Aminoglycoside 
Nebulization PARI-LC® PLUS 
300 mg nebulized twice daily 
Improved lung function, 
prevention of pulmo-
nary exacerbations 
CF 
COPD 
CB 
VAP 
CAP 
BRAMITOB® 
Chiesi Farmaceutici 
Tobramycin 
Aminoglycoside 
Nebulization- 300 mg nebulized twice 
daily 
Improved lung function, 
prevention of pulmo-
nary exacerbations 
CF 
CAP 
TOBI®- Tobramycin PulmoS-
phere™ inhalation powder USP 
(TIP)  
Novartis 
Tobramycin  
Aminoglycoside 
Podhaler- 112 mg (28 mg/capsule) 4 
capsules twice daily 
Improved lung function, 
well tolerated and safe, 
prevention of exacerba-
tions 
CF 
COPD 
CB 
VAP 
CAYSTONE® 
Aztreonam inhalation solution 
(AZLI)  
Gilead Sciences Inc. 
Aztreonam lysine 
Monobactam 
PARI eFlow nebulization- Altera® 
handset 75 mg thrice daily 
Safe and efficacious in 
prevention of lung ex-
acerbations, no antibi-
otic resistance evident, 
superior lung function 
improvement to TIS 
CF 
COLOMYCIN® 
Forest Laboratories 
Colistimethate sodium 
Polymyxin 
PARI eFlow® nebulization 80-160 mg 
twice daily 
Eradication of 
P.aeruginosa 
CF 
PROMIXINE® (TADIM®) 
Profile Pharma Ltd. 
Colistimethate sodium 
Polymyxin 
I-neb® AAD® Nebulization 80-160 
mg twice daily 
Eradication of 
P.aeruginosa 
CF 
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(Table 2) Contd…. 
 
FORMULATION NAME ANTIMICROBIAL DEVICE AND DOSE ADVANTAGES INDICATIONS 
COLOBREATHE® 
Forest Laboratories 
Colistimethate sodium 
Polymyxin 
Turbospin inhaler device- 125 mg 
twice daily 
Safe, well tolerated, effi-
cacy similar to TIS 
CF 
NEBUPENT®  
APP Pharmaceutical, LLC 
 
Pentamidine isethionate 
Antifungal 
Respirgard® II Nebulizer System-300 
mg/4 weeks 
Safer as compared to its 
parenteral form Pen-
tamidine 300 or Penta-
carinat 
Pneumocystis 
carinii pneumonia 
AEROQUIN™ 
Levofloxacin inhalation solution 
(Aptalis Pharma, Inc/ Forest 
laboratories) 
Levofloxacin  
Fluoroquinolone 
PARI eFLOW® nebulization 
In study 3 dose levels-120 mg or 240 
mg once daily or 240 mg twice a day 
Decrease in P.aeruginosa 
density, reduced need for 
other anti-P.aeruginosa 
antibiotic, well tolerated, 
broad spectrum activity 
Similar efficacy to TOBI 
in CF patients from Phase 
III clinical trial studies 
CF 
COPD 
 
Table 3. Aerosol antibiotics in clinical trials [42, 43, 47, 48]. 
FORMULATION NAME ANTIMICROBIAL DEVICE AND DOSE ADVANTAGES INDICATIONS 
ARIKAYCETM 
Liposomal amikacin for inhalation 
Insmed Inc. 
(Phase III clinical trials) 
Amikacin  
Aminoglycoside 
PARI eFLOW® nebulization 
560 mg once daily 
Sustained release of 
Amikacin, well toler-
able, reduction in 
P.aeruginosa density 
CF 
Non-tuberculous mycobac-
terial infections 
ABELCETÂ® (Aerosolized Abel-
cet®) 
Amphotericin B lipid complex for 
nebulization 
(Phase II clinical trials) 
Amphotericin B 
Antifungal 
50 mg nebulized once daily 
for four days 
Reduction in parenteral 
side effects of Abelcet® 
viz. nausea, vomiting, 
disseminated fusariosis 
and withdrawal 
Invasive fungal infections 
in pediatric patients with 
acute leukemia 
CIPROINHALE 
 Ciprofloxacin PulmoSphere™ 
inhalation powder (CPIP) 
Bayer HeathCare 
(Phase III clinical trials) 
Ciprofloxacin  
Fluoroquinolone 
Powder Inhalation 
In study at 2 dose levels-  
32.5 mg or 48.75 mg twice 
daily 
High concentration in 
the lungs, decrease in 
P.aeruginosa density 
CF 
COPD 
Non-CF bronchiectasis 
 
patients in the intensive care unit, and is also associated with mor-
tality in cases of pulmonary hospital-associated pneumonia (HAP), 
namely ventilator-associated pneumonia (VAP) and bronchoscope-
associated pneumonia [55]. This pathogen has also been associated 
with exacerbations of pulmonary conditions such as cystic fibrosis 
and COPD, primary bacteraemia in AIDS patients, malignant ex-
ternal otitis in diabetes’, contact lens keratitis and traumatic en-
dophthalmitis to name a few. It is also sometimes involved in pul-
monary community-acquired pneumonia (CAP), being the third 
most common causative agent after Streptococcus pneumoniae and 
Legionella spp [55]. 
Pseudomonas aeruginosa and Cystic Fibrosis 
 CF manifests a clinical syndrome exemplified by chronic infec-
tions affecting pulmonary, gastrointestinal, nutritional and urinary 
tracts leading to various abnormalities [56]. Pulmonary infections 
associated with CF are unique as they are characterized by various 
features, such as multiple host and parasite functions, metabolic 
disorder and restriction of infection to pulmonary tissue without any 
evidence of spreading systemically [57]. It is a severe monogenic 
autosomal recessive disorder arising from mutations in a single 
gene on the long arm of chromosome 7 which encodes the cystic 
fibrosis transmembrane conductance regulator (CFTR) protein. i.e. 
a member of ATP binding cassette family of transporters [56, 58, 
59]. CFTR, a cAMP-regulated epithelial chloride channel, is a large 
glycoprotein channel expressed on epithelial cells largely responsi-
ble for Cl- transport and also for transport of other ions, namely Na+ 
and HCO3
-. Movement of water is also a function of this channel, 
maintaining fluidity in the various epithelial linings. In CF patients, 
viscid mucus is formed, due to CFTR dysfunction, which leads to a 
lack of transport of Cl- and water across the airway epithelium and 
excessive Na+ reabsorption. This leads to formation of a dehydrated 
airway surface fluid (ASL)/ bronchoalveolar lavage (BAL) fluid. 
Viscid mucus leads to poor mucociliary clearance, entrapment of 
bacteria in the BAL fluid and inflammation [56, 58].  
 Despite an impressive understanding of the molecular basis and 
pathophysiology of the disorder, CF still prevails as a life-
threatening genetic disorder causing many medical problems ulti-
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mately resulting in premature death [56, 59]. Initially CF is associ-
ated with gastrointestinal disorders and pneumonia due to Staphylo-
coccus aureus or Haemophilis influenza. However, these can be 
eradicated using antibiotics and patients lead a relatively normal life 
with appropriate gastrointestinal symptom control. With the advent 
of P. aeruginosa colonization, a myriad of medical disorders begin. 
There is rapid exacerbation and remission of the disease and forma-
tion of a large number of P. aeruginosa cells (up to 108 organ-
isms/ml) in the sputum and the extra mucus produced is sufficient 
to hold the pathogen at the pulmonary site, which cannot be killed 
by the alveolar macrophages on their own [60]. Additionally, P. 
aeruginosa adapts to anaerobic growth; obstruction of the bronchi-
oles with mucus and low residual oxygen, leading to a low redox 
potential [57]. The organisms shed cell wall components, flagella, 
bacterial DNA and lipopolysaccharide all being immunostimulatory 
lead to a rapid proinflammatory response and formation of sero-
type-specific antibodies in the BAL fluid. However, these along 
with alveolar macrophages are ineffective in mediating opsonic 
uptake and killing of the pathogens. A study performed by Fick and 
colleagues showed that P. aeruginosa forms elastase which is capa-
ble of cleaving human IgG into fragments of less biological activ-
ity, such as Fab, F(ab’)2 and Fc which have been obtained from 
BAL fluids of CF patients. This has been shown to be the reason for 
failure of the host defence system in eradicating the pathogen. 
Rather, human host-defence systems lead to more damage due to 
loss of granular contents from phagocytic cells, polymorphonuclear 
accumulations, excessive interleukin-8 and complement cleavage 
which leads to chronic inflammatory stimulus causing destruction 
of lung tissue [60].  
Other Microorganisms and Cystic Fibrosis  
 Apart from the abundance of P. aeruginosa, other species of 
microorganism have been identified and isolated from the sputum 
and BAL of CF patients. These include other pseudomonal orga-
nisms, such as Pseudomonas maltophilia, Pseudomonas fluores-
cens, Pseudomonas alicaligenes and Pseudomonas cepacia. The 
frequency of colonization by P.cepacia has increased greatly in the 
past decade. Infection leads to high fever, high leukocyte counts, 
pulmonary complications and is a causative agent leading to death 
in CF patients [57]. 
 Other bacteria also found are Staphylococcus aureus, Haemo-
philus influenzae, Sreptococcus pneumoniae, Escherichia coli, 
Klebsiella spp, Proteus spp. etc. However these are not as chronic 
as the pseudomonal species. Acute exacerbations in CF are also 
associated with viruses, chlamydia and mycoplasmas. Fungal 
growths of Aspergillus fumigate and Candida albicans have also 
been isolated [57]. 
Pseudomonas aeruginosa and Chronic Obstructive Pulmonary Dis-
ease (COPD) 
 Chronic bronchitis is associated with cough and abnormal spu-
tum production which on further complication leads to obstruction 
of the airways leading to COPD. COPD is the 3rd leading cause of 
death in the United States and the 6th worldwide [61, 62]. Patho-
genesis of COPD is unknown; however, it has long been associated 
with cigarette smoking, inflammation and infections. Exacerbations 
of COPD lead to a reduction in health-related quality of life, in-
creasing the cost of treatment, morbidity and ultimately mortality. 
Bacteria have been found to be the cause of acute exacerbation in 
50-80% of COPD patients, predominately due to Streptococcus 
pneumonia, Haemophilus influenza and Moraxella catarrhalis, as 
well as other Gram-negative organisms such as Pseudomonas and 
Enterobacteriaceae spp [61, 62]. P. aeruginosa is being investi-
gated as a causative pathogen for exacerbations in severe COPD 
cases [63]. It has been isolated from 4-15% of adults with severe 
COPD requiring mechanical ventilation. COPD has been associated 
with increased bacterial mutation rates, increased resistance to anti-
biotics and greater biofilm production which is comparable to CF 
even though these two disease have completely different patho-
genesis [63]. 
 In COPD, airways inflammation with neutrophils and eosino-
phils has been evident in induced or expectorated sputum and BAL 
fluids. Neutrophils and eosinophil causing inflammation are associ-
ated with bacterial and viral infections respectively. Increased in-
flammation leads to increased bronchial tone with oedema in the 
bronchial wall and increased mucus production. Other clinical con-
ditions associated with inflammation in COPD are cough, dysp-
noea, increased sputum production and worsening of gas exchange 
due to loss in respiratory functions of the lungs [62].  
Pseudomonas aeruginosa and Hospital-Acquired Pneumonia 
(HAP) and Community-Acquired Pneumonia (CAP)  
 For the past two decades there has been increasing prevalence 
of P. aeruginosa as a hospital-acquired pathogen. It is now the most 
frequently isolated Gram-negative organism from patient respira-
tory tracts and within intensive care units.  
 Pseudomonas aeruginosa has been isolated from the broncho-
alveolar lavage (BAL) fluids of patients with Vapour-associated 
pneumonia (VAP). VAP caused by P. aeruginosa has a high mor-
tality rate (32 to 43%) even if patients are receiving appropriate 
antibiotic treatment [64].  
 Pseudomonas aeruginosa has also been associated with Bron-
choscope-associated pneumonia. Bronchoscopes in hospitals, due to 
defects in their design, damage or improper disinfection provide an 
appropriate environment for growth of P. aeruginosa [64].  
 Psuedomonas aeruginosa has been associated with CAP being 
the third most common pathogen after Streptococcus aureus and 
Legionella pneumophila. However, it is associated with severe CAP 
that necessitates admissions to ICU, with an occurrence of 1.8-8.3% 
and a mortality rate of 50-100% [64].  
 According to the guidelines laid by Infectious Disease Society 
of America/American Thoracic society (IDSA/ATS) and European 
Respiratory society (ERS), levofloxacin is recommended as a 
monotheraphy for CAP and in conjunction with ?-lactam antibiotic 
for HAP. However, the choice of antibiotics is based on the causa-
tive organism [65]. 
Intracellular Pathogens 
 Eradication of intracellular infections faces challenges due to 
the difficulty of access in the protective environment within cells. 
Some organisms, such as mycobacteria spp., salmonella spp. and 
Neisseria spp. etc. are primary located in phagocytic intracellular 
compartments, including macrophages, polymorphonuclear leuko-
cytes, neutrophils, etc. which recognize pathogen-associated mo-
lecular patterns (PAMPs) present on the surface of pathogens which 
are unique to the pathogen type. These proteins expressed on the 
pathogens are essential for their pathogenicity [66-70].  
 Mycobacterial infections: Tuberculosis (TB), a ubiquitous and 
highly contagious chronic bacterial infection caused by the bacillus 
Mycobacterium tuberculosis has re-emerged dramatically since the 
mid-1980s, particularly since the emergence of HIV infection, 
which renders the host 20-30 times more susceptible to infection by 
mycobacterium [71]. According to the WHO Global Tuberculosis 
Report 2013, TB affected about 8.6 million people in 2012, of 
which 1.3 million died from TB [72]. Additionally, strains of myco-
bacterium which are resistant to the first-line drugs, like isoniazid 
and rifampicin. have a high prevalence (3.6%) amongst newly 
emergent TB cases worldwide [73]. Although TB can be both pul-
monary and extrapulmonary, the pulmonary tract is a major portal 
of entry for mycobacterium, is the initial site of the immune re-
sponse and is the site of resurgence of the disease. Mycobacterium 
tuberculosis has been shown to bind to and internalize into the al-
veolar macrophages, where it enhances its survival by suppression 
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of macrophage immune responses ultimately leading to the patho-
genesis of tuberculosis tuberculosis [68, 70, 74], and spreads to 
cause extra-pulmonary TB which becomes very difficult to control. 
4.2. Fungal Infections 
 In the past few decades due to concurrent increases in organ 
transplantations, aggressive antineoplastic therapies, and 
immunocompromised patients; the prevalence and severity of 
pulmonary fungal infections has increased [75]. These infections 
have a lethality rate of 30-80% in immunocompromised and organ-
transplant patients [76, 77]. The airways, being the major portal of 
entry of fungal spores, causing such infections, suggests direct 
pulmonary administration of anti-fungal agents to the lungs using 
inhaled drug delivery, could be an attractive way to treat invasive 
pulmonary fungal infections [75, 78].  
 Common fungal pathogens which infect the pulmonary tract are 
those that cause [79]: 
1) Invasive pulmonary aspergillosis- Aspergillus fumigatus, As-
pergillus flavus, virulent species of Aspergillus terreus and 
A.astus that are resistant to treatment by azoles and ampho-
tericin.  
2) Pulmonary candidiasis- Candida albicans. 
3) Pulmonary mucormycosis- Rhizopus, Mucor and Rhizomucor 
spp. 
4) Pulmonary cryptococcosis- C. gattii and C. neoformans. 
5) Pulmonary blastomycosis- B. dermatitidis. 
6) Pulmonary histoplasmosis- H. capsulatum. 
7) Pulmonary coccidioidomycosis- Coccidioides immitis and C. 
posadasii [79]. 
 Pneumocystis pneumonia has emerged as a serious healthcare 
problem due to the increased incidence of HIV which causes weak-
ening of the patients’ immune systems leading to infection with 
opportunistic fungus Pneumocystis jirovecii. This infection invades 
the alveolar lumen in the lungs of susceptible hosts, blocking oxy-
genation, leading to death [80]. 
5. LIMITATIONS OF CURRENT ANTIMICROBIAL  
THERAPY 
5.1. Intracellular Pathogens 
 Intracellularly bacterial infections are major causes of morbid-
ity and mortality. Almost every bacterium has shown the ability to 
adapt and develop to form stronger and less susceptible variants to 
current antibiotic treatments, as evidenced by the high incidence of 
multi-drug resistant bacterial infections. This represents a consider-
able public health and economic burden as these variants are diffi-
cult to eradicate and more expensive to treat. This highlights the 
importance of developing new and improved methods of bacterial 
eradication. However, development of new chemotherapy ap-
proaches to combat the rapidly growing resistant strains of bacteria 
is too slow, threatening our ability to treat infectious diseases in the 
near future [81]. 
5.2. Biofilms 
 Microbiological research focuses predominantly on planktonic 
state cells, i.e. bacterial cells floating in culture to study antimicro-
bial activity. However it has now been established that in more than 
80% of microbial infections the bacteria grow as a protected struc-
tured community of sessile cells encased in a self-produced hy-
drated polysaccharide slimy matrix [82-84]. Initially, a layer is 
formed at a surface, i.e. the foundation of the biofilm made up of 
organic/inorganic substances deposited and adhered to a substrate 
by gravitational sedimentation or settling. This provides nutrients 
and an anchor for the bacteria. Planktonic bacteria from the bulk 
liquid are then adsorbed and start forming micro-colonies onto this 
conditional layer by physical processes such as steric interactions, 
electrostatic interactions and Van der Waal forces or by bacterial 
appendages such as flagellae, pili and fimbriae. These then develop 
irreversible attachments by secretion of polysaccharide intercellular 
adhesion proteins and divalent cations that consolidate the surface-
bacteria bond. These structures contain channels in which nutrients 
for the bacterial cells are circulated, and hence there is a rapid 
population growth of daughter sessile bacterial cells which adapt to 
the biofilm environment by changes in the expression of genes and 
in the surface properties of bacterial cells, and grow together in 
nascent clusters. The final stage of biofilm development is com-
pleted by quorum sensing (QS) cell signalling mechanisms, wherein 
stimulation of genetic expression takes places leading to production 
of alginate which forms a part of the extracellular matrix of the 
biofilm, along with many other signal molecules that help in co-
ordination of the biofilm bacteria. These signals govern processes 
such as bacterial dispersion which is essential to prevent over-
growth of the rapidly dividing bacteria, and their escape and coloni-
zation of new niches when nutrients become limited and waste 
products accumulate [85]. 
 Numerous mechanisms are involved in the avoidance of antibi-
otic challenges by biofilm-associated bacteria. One mechanism is 
the failure, retardation or reduction in penetration and diffusion of 
antibiotics into the full depth of the biofilm due to the presence of a 
physical polymeric barrier. A further mechanism is a change in the 
microenvironment of the biofilm. Studies have shown that there are 
anaerobic niches in the deeper regions of the biofilms, rendering 
some antibiotics, such as those of the aminoglycoside class inactive. 
Moreover, accumulation of waste products may cause a change in 
the pH of the biofilm niche which can directly cause inactivation or 
antagonism of certain antibiotics, limiting their activity. Addition-
ally alteration in the osmotic environment leads to an osmotic stress 
response, ultimately resulting in a reduction in the permeability of 
bacteria to antibiotics by altering the proportion of porins in the 
bacterial cell wall. A further proposed mechanism to explain re-
duced biofilm susceptibility is the development of slow-growing or 
non-growing dormant bacterial cells which become less susceptible 
to antibiotics, e.g. penicillin antibiotics which target cell-wall syn-
thesis bacteria [82, 83]. 
5.3. Bacterial Resistance 
 Historically, treatment failures to antibiotics due to resistance 
were not given a great deal of importance as other antibiotic classes 
were available. However, relatively quickly multiple resistance to 
numerous antibiotic developed, which now represents a consider-
able therapeutic challenge. The first global report on antibiotic re-
sistance by the WHO in 2014 revealed a serious threat worldwide 
and the need for urgent interventions to combat an imminent future 
crisis [86]. Multi-drug resistant tuberculosis (MDR-TB) has 
emerged swiftly, representing a global health concern, threatening 
TB control and treatment worldwide [87]. WHO has reported a 
doubling in the people diagnosed with MDR-TB between 2011 and 
2012, with 0.45 million new incidences of MDR-TB and an occur-
rence of 0.17 million deaths in 2012 due to MDR-TB [72, 73]. In-
stances of extensively drug resistant (XRD-TB) and totally drug 
resistant (TDR-TB) cases have risen persistently in the past decade, 
posing a major challenge to the limited, time consuming treatment 
options currently available to treat TB. 
 Bacterial resistance to antibiotics can be innate or acquired by 
genetic and phenotypic modifications. A speculative hypothesis 
explaining reduced antibiotic susceptibility is the development of 
resistance due to genetic chromosomal mutations of the bacteria. 
These can result in (1) reduced permeability or uptake of the antibi-
otic, e.g. resistance to chloramphenicol antibiotics due to decreased 
permeability into Gram-negative bacteria. Resistance to penicillin 
and tetracycline is evident in Neisseria gonorrhoea due to reduced 
permeability of the antibiotics [88]; (2) increased efflux activity of 
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the antibiotic from the bacterial cell, e.g. in the presence of tetracy-
cline, the TetK gene responsible for efflux, transcription and trans-
lation is activated leading to an increase in the number of efflux 
pumps and consequently resistance to tetracycline antibiotics [89]. 
Up-regulation of the norA gene in S. aureus leads to an increase in 
efflux pumps leading to fluoroquinolone antibiotic resistance; (3) 
enzymatic inactivation of antibiotics, e.g. ?-lactamases catalysing 
ring-opening of ?-lactam antibiotics. Aminoglycoside antibiotics 
are inactivated by addition of acetyl, adenyl and phosphoryl groups 
onto the antibiotic by aminoglycoside-inactivating enzymes [90]; 
(4) alteration of the drug target site, e.g. alterations in the target site 
of DNA gyrase subunit A and B are responsible for resistance 
against fluoroquinolone antibiotics [91]. Resistance against rifam-
picin arises from mutation in the ? sub-unit of the RNA polymerase 
site required by the drug to show activity. Streptomycin resistance 
has been evident due to target site mutation on the rrs gene encod-
ing 16s rRNA [92], and (5) loss of enzymes necessary for activation 
of the antibiotic, e.g. inactivation of the katG gene leads to reduced 
catalase activity and hence ineffective conversion of isoniazid into 
its active hydrazine derivative. Inactivation of pyrazinamidase by 
mutation in the pncA gene required for conversion of pyrazinamide 
to its active form pyrazinoic acid results in loss of antimycobacte-
rial activity of the antibiotic [93, 94].  
 Further, phenotypic modifications involve sessile bacteria in 
biofilms that grow as spore-like biologically programmed bacterial 
subpopulations which are unique and highly protected dormant 
phenotypes, which are resistant to antibiotics in the dormant state. 
Another type of phenotypic modification involves the presence of 
salicylates, such as aspirin which make bacteria, including Pseudo-
monas, Mycobacterium tuberculosis and E.coli etc. less susceptible 
to common antibiotics due to an increased antibiotic efflux and 
reduced permeability, by a reduction in the level of porin expres-
sion [95].  
5.4. Sputum 
 Mucus in the healthy lung is 10-30 ?m thick in the trachea and 
2-5 ?m thick in the bronchial regions. This thickness allows easy 
diffusion of gas, nutrients, ions, proteins, etc., and the entrapment 
of particulate matter which is then efficiently removed by the mu-
cociliary clearance process. Chronic lung diseases, such as COPD, 
chronic bronchitis, asthma and CF are associated with impaired 
mucociliary clearance and necrotic death of epithelial and inflam-
matory cells in patients’ lungs leading to bronchiectasis and deposi-
tion of thick, stationary, tenacious mucus plaques where heavy 
colonization of bacteria especially by P. aeruginosa is evident, due 
to the availability of a nutrient rich environment that is optimal for 
bacterial growth [96-98]. This viscoelastic and adhesive mucus 
secretion acts as a physical barrier and hinders diffusion of antibiot-
ics and acts as an electrostatic barrier. Necrotic cells contribute to 
excess release of a network of copolymerized polyanionic contents 
including DNA, mucin glycoproteins and F-actin which physically 
bind to polycationic antibiotics, such as tobramycin leading to their 
deactivation [96, 98, 99]. Antibiotics delivered for treating bacterial 
infections associated with these diseases needs to penetrate the 
sputum and distribute evenly. Drugs such as ion-channel modula-
tors or gene therapeutics which need to reach the epithelial layer 
must first traverse the thick mucus layer to achieve their desired 
activity [100, 101]. 
 There are steep hypoxic gradients in the airway sputum which 
have been shown to activate the genes responsible for anaerobic 
respiration of P. aeruginosa, and hence cause a conversion of the 
bacteria from the non-mucoid to the resistant extracellular polym-
eric substance (EPS)-producing mucoid mutant [98, 102, 103]. This 
mucoid mutant secretes alginate in which microcolonies of the bac-
teria are embedded, providing increased resistance to phagocytes, 
opsins and antibiotics [98, 102-104]. The increased presence of 
mucin glycoproteins in the sputum of patients immobilizes P. aeru-
ginosa by surface interactions, which has increased tolerance to 
antibiotics resisting clearance from these hypoxic mucopurulent 
masses in the airway [98, 105]. The CF sputum is the reason for 
failure of drug delivery and hence treatment [100, 101]. Moreover, 
antibodies and fragments along with other soluble factors act as 
molecular traps for viral gene delivery, as demonstrated for adeno-
viral gene delivery due to the presence of adenoviral antibodies 
[100]. 
6. DRUG DELIVERY SYSTEMS 
 Researchers have made great advances in engineering new 
nanotechnology-based carrier systems for different pulmonary ap-
plications. The choice of delivery system largely depends on factors 
such as:  
Disease Condition  
 This is a crucial parameter which dictates the choice of delivery 
system. For different disease conditions, varied formulations are 
required to transport the drug to the particular site of action and 
impart desired pharmacological effect. Delivery of water insoluble 
drugs and highly unstable drug molecules may be achieved by load-
ing them into nano-delivery systems. For the systemic delivery of 
insulin for the treatment of Diabetes Mellitus, nanoparticle dry 
powders have been marketed as Exubera® (Pfizer; now withdrawn) 
and Afrezza™ (MannKind) which is a Technosphere™-based in-
haled insulin product. Both of these need to be deposited in the 
alveoli, and hence require an optimized delivery device [106-108]. 
On the other hand, local administration of anti-tubercular drugs 
needs a delivery system which not only transports drug to the alveo-
lar macrophages but also has the capacity of being endocytosed by 
these macrophages [106]. However, endocytosis of ?-agonists leads 
to their inactivation and clearance leading to loss of efficacy, hence 
formulations with minimal macrophage uptake properties would be 
needed [106]. Delivery of nanoparticles encapsulating antibiotics to 
the lung for treatment of infections associated with CF, COPD or 
pneumonia etc. can present a great challenge due to the thick vis-
coelastic mucus barrier in the lung. To traverse this barrier, 
nanoparticles must have a small size and should ideally be designed 
with a muco-inert surface so as to prevent their adhesion to mucin 
fibres which are highly prevalent and pose as a severe hurdle to 
delivery of antibiotics to the site of infection in these disease condi-
tions [109].  
Retainment of Pharmacological Effect  
 The formulation and preparation of the delivery system should 
not affect the pharmacological activity of the drug. The release 
profile of the drug should be optimized to achieve maximum drug 
efficacy and duration of activity [108]. 
Fate of Delivery System  
 This is important criterion needs careful consideration. Varied 
delivery system engineering parameters, such as shape, size, mate-
rials, aggregation state, surface charge, chemical properties, formu-
lation, etc. may each affect the toxicity profiles [110]. The small 
size of these new delivery systems imparts them with new physical 
and chemical properties different from conventional bulk drug pow-
ders [111]. It has been observed that multi-walled carbon-nanotube 
based delivery systems have the capacity to collect in the subpleural 
regions of the lung, leading to pulmonary fibrosis, multifocal 
granulomatous inflammation, diffuse histiocytic and neutrophilic 
inflammation, intra-alveolar lipoproteinosis etc. [110, 112]. Inhaled 
nanoparticles can not only cause inflammation and other 
exacerbations, but may also interfere with the functioning of the 
pulmonary system. Nanoparticles fabricated of polystyrene, gold or 
titanium dioxide have been reported to alter the function and struc-
ture of pulmonary surfactant and hence impede its ability to de-
crease surface tension rapidly during a normal breathing cycle 
[113]. Clearance of nanoparticles in alveolar region is mediated by 
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alveolar macrophages. These recognize nanoparticles, phagocytize 
them, travel to the mucociliary escalator and are cleared. However, 
this process is very slow and the retention half-life of solid particles 
deposited in the alveolar region of humans is 700 days. Moreover, 
larger particles are not easily phagocytized nor are ultrafine 
nanoparticles [114]. 
 The various delivery systems which can be used to deliver an-
timicrobials to the site of infection in the lung are: 
6.1. Liposomes 
 Liposomes are lipid-based carrier systems which have been 
widely used as drug carriers for cosmeceutical and pharmaceutical 
applications and are the most studied delivery system for the deliv-
ery of a variety of therapeutics [115, 116]. Liposomes are self-
assembling structures which due to intrinsic interfacial properties 
imparted by the phospholipids spontaneously form spherical vesi-
cles in aqueous media. These vesicles are made up of one or more 
concentric phospholipid bilayers alternating with aqueous com-
partments, with sizes ranging from 0.05-50 ?m. Hydrophobic and 
amphiphilic drugs can be incorporated within the lipid bilayers, 
whereas, hydrophilic drugs can be encapsulated in the aqueous 
compartments/core. They are safe, non-toxic, biodegradable, bio-
compatible delivery systems for encapsulation of a wide range of 
drugs having varied properties, including molecular size, charge, 
hydrophobicity etc. They interact with living cells by adsorption, 
endocytosis, lipid exchange and/or fusion [116-118]. Liposomes 
can be divided into categories based on the basis of their size and 
lamellarity; namely small unilamellar vesicles (SUV), large uni-
lamellar vesicles (LUV) and multilamellar vesicles (MLV), or on 
the basis of their properties, for instance immunoliposomes, stealth 
liposomes, proteoliposomes, pH-sensitive liposomes, charged 
liposomes etc. [116, 117, 119]. Liposomes can be prepared using a 
number of techniques, the most frequently used of which are the 
thin-film method, reverse-phase evaporation, solvent injection, 
freeze-thaw extrusion and ultrasonication [119]. 
Liposome Delivery to the Lung  
 These are an attractive delivery system to the lung as they can 
be made of surfactants which are endogenous to the pulmonary 
tract. The first pulmonary-delivered liposomal product being Alve-
ofact® (LyomarkPharma), instilled to the lung for treatment of 
pulmonary distress syndrome. Deposition of liposomes, aerosolized 
with jet nebulizers, into the non-ciliated peripheral regions of the 
lung results in prolonged greater retention of the liposome-
associated drug within the lung [120, 121]. Cationic liposomes have 
been successful in aerosol delivery of gene [114, 122, 123], while 
liposomes conjugated with cell-penetrating peptides can act as po-
tential carriers of macromolecules to the lungs [114]. Modification 
of the liposome surface with O-stearylamylopectin has been shown 
to increase lung tissue affinity [116], while conjugation of 
liposomes with octaargine or antennapedia enhanced cellular uptake 
in the airway [114]. Conjugating mannose to liposomes produces 
superior macrophage uptake to non-conjugated liposomes, with 
potential application in the treatment of diseases such as rheumatoid 
arthritis, tuberculosis, leishmaniasis, etc. where the macrophages 
play a very important role in the disease [124, 125]. Stability of the 
vesicles, vesicle delivery and the size properties of the aerosol 
cloud are major considerations when atomizing liposomes using 
nebulizers, and are functions of both formulation properties and the 
nebulizer system employed. Bridges et al. [126] showed the signifi-
cance of lipid concentration in determining the droplet size of the 
aerosols generated from two different jet nebulizers, namely Pari-
LC and Sidestream. Increasing the egg phosphatidylcho-
line/cholesterol lipid concentration from 5 to 80 mg/ml led to a 
reduction in output of the liposomes from both the nebulizers for 
liposomes of 5 ?m, with the mean droplet size of the aerosol gener-
ated being 2 ?m. Whereas fluid liposomes could be size reduced in 
the nebulizer and delivered in the aerosol, rigid liposomes failed to 
be aerosolized, whilst increased lipid concentrations resulted in a 
rise in viscosity with subsequent reduction in aerosolization [126]. 
Bridges et al. [120] also highlighted the importance of liposomal 
constituents for determining the damage caused to liposomes during 
nebulization by ultrasonic and jet nebulizers. Fluid egg phosphati-
dylcholine liposomes were size reduced on aerosolization using 
both devices, which will cause loss of entrapped hydrophilic drugs, 
whilst incorporation of cholesterol or use of lipids which having a 
high phase transition temperature, such as DPPC imparted rigidity 
to the bilayers, resulting in liposomes more resistant to the shearing 
forces occurring during aerosolization [120]. Chattopadhyay et al 
[127] highlighted the importance of bilayer composition, namely 
neutral or charged lipids and presence of cholesterol on the mor-
phology and bilayer integrity of small liposomal suspensions, size 
range 80-130 nm, nebulized using a jet nebulizer. Aerosolization of 
the liposomes consisting of DPPC, DSPG (charged lipid), DPPC: 
DSPG: DSPE-PEG and DPPC: DSPG: Chol demonstrated that 
addition of charged lipids reduced aggregation due to electrostatic 
repulsion during nebulization, as compared to uncharged liposomes 
(DPPC), however, such liposomes had a greater loss of encapsu-
lated dye due to increased membrane rupture. On the other hand, 
addition of cholesterol along with the charged lipid (DPPC: DSPG: 
Chol) helped in reduction of aggregation and higher retention of 
dye (>85%) [127]. Studies have emphasized the importance of the 
nebulizer used in conjunction with liposomal systems. Use of a 
vibrating mesh nebulizer Aeroneb® for aerosolization of DPPC 
liposomes encapsulating Iloprost for pulmonary arterial hyperten-
sion showed significant advantages due to reduced drug loss and 
change in liposomal size compared the jet nebulizer Pari LC® star 
or ultrasonic nebulizer Optineb® [128]. The relationship between 
nebulizer performance and formulation development requires in-
depth knowledge of formulation properties and the working princi-
ples of the various nebulizer types. An attractive approach would be 
to deliver liposomes by DPIs produced by spray drying the lipo-
somes and relying on their hydration in situ on delivery to the moist 
airways [129, 130].  
Liposomes and Antimicrobials  
 The properties of liposomes can be easily manipulated and a 
variety of including antimicrobials can be incorporated within them. 
By encapsulating antimicrobials into liposomes, improved delivery 
may be achieved, for instance by targeting macrophages where 
infections reside, or due to their small size they can pass through 
biofilms and reach peripheral sites for complete bacterial eradica-
tion [117, 131]. Rifampicin, an anti-mycobacterial drug used for 
tuberculosis treatment shows a very high rate of hepatotoxicity and 
nephrotoxicity, along with other side effects, including thrombocy-
topenia, immune haemolytic anemia and intravascular haemolysis 
due to its high metabolism in these organs leading to idiosyncratic 
metabolites which are toxic to these organs on oral delivery [132-
136]. Encapsulation of rifampicin into pulmonary-delivered 
liposomes improves its toxicity profile and reduces hepatotoxicity 
[137-139]. Various liposomal systems for pulmonary delivery of 
antifungals, antimycobacterials and other antimicrobials have been 
described in literature, a few of which have reached clinical trials, 
as summarized in Table 4. 
6.2. Polymeric Microparticles and Nanoparticles 
 Microparticles are in the micrometer size range and can be clas-
sified as microspheres i.e. uniform spheres constructed of polym-
eric matrices, or microcapsules i.e. a thin polymer membrane en-
capsulating an oily core [156]. Nanoparticles can also be used for 
pulmonary delivery; however, due to their small size they may be 
exhaled and hence not deposit in the airways. To overcome this 
drawback they can be delivered by nebulization after suspending in 
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Table 4. Liposomal antimicrobial therapies under investigation. 
ANTIMICROBIAL MICROORGANISM ADVANTAGES 
Amikacin 
Aminoglycoside 
DPPC: Chol liposome 
ArikayceTM (Insmed Inc.) 
Clinical trials phase III 
Pseudomonas aeruginosa 
(Inhalation-nebulization) 
 
Comparison of Arikayce™ versus placebo nebulized to the lungs showed 
beneficial results as liposomal amikacin had susceptibility to cross mucus and 
biofilm present in patients suffering from CF, hence, sustained and significant 
improvement in lung function and reduction of pseudomonas density [140] 
Amikacin 
Aminoglycoside 
HSPC: Chol: DSPG (2: 1: 0.1) 
MiKasome® (NeXstar Pharmaceuticals, 
Inc) 
Mycobacterium tubercu-
losis 
Increased uptake by the mononuclear phagocyte system showed benefits 
especially for multi-drug resistant M.avium, wherein, increased killing is 
evident versus free amikacin which fails to reach high intracellular effects and 
shows ototoxicity and nephrotoxicity [141-144] 
Tobramycin 
Aminoglycoside 
Fluidosomes 
(Axentis Pharma) 
Clinical Trial II 
Pseudomonas aeruginosa 
Escherichia coli 
Staphylococcus aureus 
[116] 
Improved management of pulmonary infections was seen on intratracheal 
administration of fluid-based liposomes encapsulated tobramycin [145] 
Riampicin+ Isoniazid 
DPPC: Chol 
Passively targeted 
Mycobacterium tubercu-
losis 
 
Increased therapeutic drug level found in the plasma on inhalation administra-
tion of a single dose in guinea pigs 
Drugs found to localize in the alveolar macrophages of the lungs [146, 147] 
Rifampicin+ Isoniazid 
DPPC: Chol: O-stearylamylopectin: DCP: 
DSPC-PEG 2K 
Actively targeted 
Mycobacterium tubercu-
losis 
 
Superior efficacy of the formulations against M.tuberculosis with a reduction 
in mycobacterial CFUs in liver, kidney and lungs. 
Reduction in nephrotoxicity associated with the free drug and normal lung 
morphology observed [137, 146, 148] 
Rifampicin 
Egg PC: Chol: O-stearylamylopectin: DCP 
or 
Egg PC: Chol: maleylated bovine serum 
albumin: DCP 
Actively targeted 
Mycobacterium tubercu-
losis 
 
The targeted liposomes showed improved lung accumulation specifically 
improved alveolar macrophage uptake and accumulation showing the feasibil-
ity of the inhalatory mode of delivery for eradication of M. tuberculosis.[146, 
149] 
No drug specified 
HSPC: Chol: DCP: MAN 
Actively targeted 
- 
 
Significantly higher internalization and selective targeting to alveolar macro-
phages in vivo with the mannose- linked liposomes compared to non-targeted 
liposomes [146, 150, 151]. 
Ciprofloxacin 
Fluoroquinolone 
 
Pseudomonas aeruginosa 
Francisella tularenis 
Brucella melitensis [116] 
Reduction of efflux mechanism and increased bacterial retention as compared 
to free drug on aerosol inhalation 
Free drug was ineffective in treating F. Tularenis [152] 
Polymyxin B 
Peptide antibiotic 
Pseudomonas aeruginosa 
 
Intratracheal instillation of liposomal polymyxin B showed higher drug 
amounts, greater retention and pronounced protective effects in lungs as com-
pared to free polymyxin B and protection from nephrotoxicity, ototoxicity and 
neuromuscular blockade [118, 153]  
Dapsone 
Sulphone antibiotic 
Pneumocystis cari-
nii pneumonia 
 
Dapsone nanoliposomes based DPI showed enhanced drug release with deep 
lung penetration due to increase in fine particle fraction to 75% reducing 
systemic toxicity and promising better treatment [140, 154] 
Ciprofloxacin-Fluoroquinolone or  
Azithromycin-Macrolide 
Mycobacterium avium 43-fold greater potency was seen against M.avium compared to free ciproflox-
acin due to increased negative charge imparted by the liposome formulation of 
DSPG: Chol [117, 155] 
CF- cystic fibrosis, TB- tuberculosis, DPI- dry powder inhalation, DSPG- distearoylphosphatidyl glycerol, DCP- dicetyl phosphate, HSPC-hydrogenated soy phosphatidylcholine, 
Egg PC- egg phosphatidylcholine, Chol- cholesterol, MAN- mannose, CFUs- colony forming units 
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a suitable liquid, with deposition governed by the size characteris-
tics of the nebulized droplets, or incorporated into larger carrier 
particles [157]. Microparticles are used as an alternative to 
liposomes, being more readily stable on storage or in the biological 
fluids, and they offer the possibility of modulation of release rate 
[158].  
 Polymers are used in different fields such as pharmaceutical, 
biomedicine, tissue engineering, cosmeceuticals, etc. [159]. Polym-
eric microspheres prepared from biodegradable or biocompatible, 
natural or synthetic polymers have been studied as delivery systems 
for pulmonary delivery, to control delivery of drugs to the pulmo-
nary tract and to protect them from enzymatic degradation. Polymer 
selection is critical for the success of the formulation, with appro-
priate control of drug release. As for all pulmonary delivery, the 
size of the nanoparticles and microparticles and their adequate dis-
persion a critical to ensure deep lung delivery [156, 157]. Particu-
late systems have a number of key parameters, including morphol-
ogy, size, size distribution, porosity, density, surface charge, sur-
face energy, controlled or sustained release etc. which are functions 
of many variables to be considered in their formulation and manu-
facture, such as: polymer lengths, surfactants, organic solvent, 
preparation methods, etc. A wide range of natural polymers, for 
instance albumin, collagen and chitosan are available, however 
users must consider a potential lack of purity, the presence of ho-
mogeneity and the possibility of disease transmission. However, 
these natural polymers can be modified, for instance the acylation 
of chitosan, to control release rate. Synthetic polymers, like 
poly(lactide-co-glycolide) (PLGA) copolymers, polyacrylates, 
poly(lactic) acid (PLA), poly(butylcyanoacrylate) and poly(lactic-
co-lysine) graft polymers and polyanhydrides are available and 
offer advantages over natural polymers as they can provide sus-
tained/controlled release, and have high purity, homogeneity and 
other desirable properties [153, 156-158]. Targeting can also be 
achieved by using ligands. For instance, lectin may be used with 
polymeric microspheres, as it binds to simple/complex carbohy-
drates on bacterial cell walls, and it has been used against Helico-
bacter pylori infections by conjugation onto gliadin nanoparticles 
[153]. 
 Polymeric nanoparticles can be prepared by various methods 
namely: emulsification-solvent removal, phase coacervation, inter-
facial polymerization and spray drying. The choice of method de-
pends on the desired size and properties of microsphere to be made, 
and physiochemical properties of drug [158]. 
 The mechanism of drug release from nanoparticles is due to 
degradation or erosion of the polymeric matrix. If the polymer ma-
trix undergoes degradation, it releases by diffusion due to polym-
eric chain breakage leading to channels created in matrix. Erosion 
of polymer matrix leads spontaneous drug release as the polymer is 
eroded [158, 159]. Technical and stability issues regarding the use 
of nanoparticles for delivery of anti-infective agents to the lung 
however prevail. To date, most nanoparticles have been aerosolized 
using nebulizers. However, storage of colloidal preparations results 
in instabilities, such as polymer hydrolysis, drug loss, particle-
particle interaction of nano/microparticles and particle aggregation. 
Previous studies have highlighted the importance of formulation 
development and nanoparticle size on aerosol size and the incorpo-
ration of particles into nebulized droplets. In addition to size, the 
surface properties of individual particles and their concentration 
play an important role in determining formulations release kinetics 
and the output from the nebulizer [160-162]. Dry powder inhaler 
formulations can be achieved by spray drying nanoparticle and 
Table 5. Polymeric microparticles described in literature for delivery of antimicrobials for treating pulmonary infections. 
POLYMER ANTIMICROBIAL MICROORGANISM ADVANTAGES 
Polybutyl cyanoacrylate 
nanoparticle 
(PBCA) 
Rifampicin 
Antimycobacterial 
 
Mycobacterium avium 
Staphylococcus aureus 
2-3 fold greater delivery of rifampicin loaded-PBCA to the 
alveolar macrophages leading to 2-fold increase in rifampicin 
efficacy compared to free rifampicin [153, 163] 
PLGA- Nanoembedded 
microparticles 
Tobramycin  
Aminoglycoside 
Pseudomonas aeruginosa PLGA-tobramycin nanoparticles embedded in respirable lactose 
microparticles and consisting of helper polymers like chitosan 
showed greater mucin interactions and behaved as drug reser-
voirs to achieve sustained drug release [164] 
Poly(lactide-co-
glycolide) 
(PLGA) 
Ciprofloxacin 
Fluoroquinolone 
Staphylococcus aureus 
Pseudomonas aeruginosa 
[140, 153] 
Nano-ciprofloxacin formulations achieved sustained release of 
drug directly at the site of pulmonary infection and appropriate 
aerodynamic particle size to achieve deep lung access for the 
drug [140, 165] 
Polyisobutyl cyanoacry-
late  
(PIBSA) 
 
Ciprofloxacin 
Fluoroquinolone 
Mycobacterium avium IV administration of Ciprofloxacin loaded- PIBSA showed 
greater activity due to higher uptake in alveolar macrophages 
compared to free ciprofloxacin [117] 
Albumin, dipalmitoyl-
phosphatidylcholine and 
lactose (DAL) 
Ceftazidime  
Cephalosporin  
Ciprofloxacin  
Fluroquinolone 
Pseudomonas aeruginosa DAL based ceftazidime and ciprofloxacin showed better stabil-
ity than nebulized solutions in which these drugs precipitate, 
successful co-deposition at desired site in desired ratio, im-
proved aerodynamics and additive antipseudomonal activity 
was achieved [166] 
Carboxymethyl chitosan 
(CMC) 
Ciprofloxacin 
Fluoroquinolone 
Escherichia coli 2-fold increase in antibacterial activity of ciprofloxacin loaded 
CMC compared to free ciprofloxacin was seen due to increased 
bacterial uptake [167] 
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microparticle dispersions, and this can be an attractive alternative 
approach to ensure the long-term stability of nano/microparticles. 
However, redispersion on aerosolization and in the pulmonary fluid 
are important criteria, and retention of the nano/micropaticle size in 
the lungs post-aerosolization can be a challenge [162].  
 Polymeric nanoparticles described in literature for pulmonary 
applications in infective disease are summarized in Table 5. 
6.3. Lipid Microparticles and Nanoparticles- Solid Lipid Nano-
particles 
 Lipid microspheres and nanospheres may be used as an alterna-
tive to polymer microspheres and liposomes. Solid-lipid nanoparti-
cles (SLNs) range from 50-100 nm and have attracted attention in 
the past 25 years due to the easy fabrication techniques. SLNs are 
viewed as a potential pulmonary delivery system due to the low 
toxicity of phospholipids employed, compared to polymer-based 
systems, higher tolerability in lungs, prolonged and controlled re-
lease properties and rapid in-vivo degradation compared to PLGA 
or PLA particles. Their composition includes: fatty acids, steroids, 
triglycerides, partial glycerides, waxes that are solids at room tem-
perature as well as surfactants to stabilize the SLNs. They can be 
prepared by simple spray drying, ultra-sonication and high pressure 
homogenization as dry powders or dispersions for delivery via a 
nebulizer [114, 153]. Lipid microparticles and nanoparticles de-
scribed in literature are summarized in Table 6. 
6.4. Micelles 
 Amphiphilic macromolecules having hydrophobic and hydro-
philic regions have a tendency to assemble in aqueous environ-
ments at a concentration greater than the critical micellar concentra-
tion into nano-sized micelles. These have widespread application 
within pharmaceutics, as hydrophobic drugs can be encapsulated 
within the hydrophobic core of the micelles, allowing formulation 
at concentrations greater than their intrinsic water solubility. 
Moreover, the micelle can provide protection from degradation of 
the drug molecules and release kinetics can be manipulated by 
chemical alterations of the micelle surface, e.g. by cross-linking. 
Micelles can be formed from polymers/lipids that have been syn-
thesized to achieve specific functionalities, such as targeting [156]. 
Polymeric micelles have been shown to be more stable than con-
ventional surfactant micelles, having critical micellar concentra-
tions less than 10-6 M [156, 169-171]. One of the most prominent 
reasons for resistance to current antibiotics is the downregulation of 
uptake receptors on the surface of microorganisms. It would be an 
attractive approach to encapsulate such antibiotics within self-
assembling micelles which would not be recognized by the receptor 
surfaces and hence help in intake of antibiotics into resistant bacte-
ria.  
 Micellar formulations encapsulating anti-microbial agents de-
scribed in the literature are summarized in Table 7. 
6.4. Large Porous Carriers 
 Large porous carriers, referred to as ‘Trojan particles’ by Tsapi 
et.al [174] are newly engineered micrometer-sized particles for 
inhaled drug delivery. These can be of two types namely:  
Large Porous Particles (LPPs) 
 These are characterized by a geometric size greater than 4 to 5 
?m and mass density less than 0.1 g/cm3, resulting in in formation 
of particles which have a small aerodynamic diameter [42, 174, 
175]. These are attractive system for pulmonary delivery as they 
have superior aerodynamic properties as compared to conventional 
particles of the same physical size. 60% of the nominal dose of such 
particles may reach the deep lung, and they are not cleared easily by 
alveolar macrophages, due to their large size. Hence they are 
attractive for sustained release of drug in the lungs [42, 176]. The 
highly porous surfaces and relatively large sizes of such particles 
help to decrease their surface energy, compared to conventional 
particle approaches, and hence inter-particulate cohesion is reduced 
and they disperse more easily in presence of airflow shear forces 
[42, 176]. This dispersion has low inter-patient variability, as it is 
independent of patients’ peak inspiratory flow [42]. 
 Large porous capreomycin particles were manufactured by 
spray drying with L-leucine from a 50% aqueous ethanol solution 
to produce particles having mass median aerodynamic diameter 
(MMAD) of 5 ?m. Insufflations delivery of these particles to 
guinea pigs resulted in reduced bacterial burdens, decreased alveo-
lar clearance and hence a potential to lower the dose and decrease 
toxic side effects [177]. Edwards et al. [178] determined the sys-
temic bioavailability of insulin and suppression of blood glucose 
levels, using large porous PLGA particles encapsulating insulin, 
prepared by solvent evaporation techniques. Inhalation of large 
porous insulin particles (mean physical diameter 6.8 ?m, MMAD 
2.15 ?m) demonstrated higher insulin bioavailaibity and glucose 
suppression for 96 h than non-porous insulin particles (mean diame-
ter 4.4 ?m, MMAD 2.15 ?m) which showed lower bioavailabity 
and glucose suppression for only 4 h. These results were attributed 
to the reduction in phagocytosis by deep lung alveolar macro-
phages, which are inefficient in removal of particles greater than 3 
?m, leading to sustained release and greater bioavailability of insu-
lin systemically [178]. 
 An established engineering technique for preparation of LPPs is 
the Novartis PulmoSphere™ Technology. These are manufactured 
by emulsion-based spray-drying, wherein submicron oil in water 
emulsion droplets are generated by high pressure homogenization 
of perfluorooctyl bromide in water. The principal lipid component 
Table 6. Solid lipid nanoparticles described in literature for delivery of antimicrobials for treatment of pulmonary infections. 
SOLID LIPID ANTIMICROBIAL MICROORGANISM ADVANTAGES 
Stearic acid, soya, phos-
phatidyl choline and so-
dium taurocholate 
Tobramycin 
Aminoglycoside 
Or 
Ciprofloxacin 
Fluoroquinolone 
Pseudomonas aeruginosa Increased drug bioavailability and prolonged drug  
release [153] 
Stearic acid Rifampicin, isoniazid or pyrazina-
mide  
Antimycobacterials 
Mycobacterium tuberculo-
sis 
Increased residence time, increased macrophage  
uptake and lymphatic system delivery achieved,  
decreased administration frequency due to increased 
bioavailability [153, 168] 
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of PulmoSpheres is distearoylphosphatidylcholine (DSPC). Drugs, 
such as tobramycin and amphotericin B are dissolved in the water 
phase of the emulsion [42]. 
 PulmoSphere formulations of anti-infectives, namely tobramy-
cin, amphotericin B and ciprofloxacin have undergone at least 
Phase II clinical trials II. Tobramycin inhalation powder- TIP™ 
(TOBI® Podhaler®; Novartis Pharmaceuticals) is safe and effica-
cious in treating P. aeruginosa lung infections in CF patients, and 
has now been licensed and is marketed in several European coun-
tries, South America and Canada [42, 43]. A questionnaire survey 
of 39 patients and their parents, as well as 54 respiratory therapists, 
revealed that TIP™ (TOBI® Podhaler®) was considered to be more 
convenient and acceptable than tobramycin inhalation solution 
(TIS™ TOBI®) [42, 179]. Ciprofloxacin PulmoSpheres (Bayer 
HealthCare) have also shown efficacy for the treatment of P. aeru-
ginosa in CF patients. Ciprofloxacin DPI was well tolerated in pa-
tients with minimal ciprofloxacin systemic adverse effects. 40% of 
the total dose was shown to reach the trachea/bronchi and alveolar 
space of the lungs, with the aim of increasing ciprofloxacin reten-
tion in the lung [180]. This formulation was successful in Phase I 
clinical trials in 2013 to evaluate the potential of ciprofloxacin DPI 
for mild to moderate COPD. It also passed Phase II studies to 
evaluate safety and efficacy in patients with CF in May 2014 [47, 
181, 182]. 
Large Porous Nanoparticle Aggregates (LPNAPs)  
 LPNAPs comprise micron-sized particles consisting of 
nanoparticles (1-100 nm) held together by van der Waals forces or 
present in matrix having components such as biopolymers, surfac-
tants, amino acids, lipids and proteins. LPNAPs have been made 
from a range of materials including silica, polystyrene, DPPC, al-
bumin, hydroxypropyl cellulose, lactose etc. in sizes ranging from 
25 to 1000 nm. LPNAPs have similar physical and aerodynamic 
properties to LPPs, and once delivered to the lungs they dissociate 
to form individual nanoparticles [174]. LPNAPS can overcome the 
problems associated with pulmonary delivery of nanoparticles, i.e. 
exhalation due to their small size, yet provide the advantages of 
nanoparticles when they are liberated in situ following deposition of 
the larger particles in the lungs. 
7. ADVANTAGES OF NANO-ANTIMICROBIALS 
7.1. Protective Vesicles Preventing Antimicrobial Degradation 
 Nanocarriers can be an attractive approach for delivery of an-
timicrobials as they provide a protective environment that shields 
the antibiotic preventing degradation. Antibiotic inactivation by 
enzymes or interactions with other components in the biofilm ma-
trix may reduce drug activity or cause complete resistance to it.  
 Mugabe et al. [183] have demonstrated that gentamicin encap-
sulated in liposomes showed superior activity than drug alone for 
eradication of resistant strains of P. aeruginosa isolated from clini-
cal CF patients. Three different liposomal formulations: DPPC: 
Chol, DMPC: Chol and DSPC: Chol encapsulating gentamicin 
showed significantly higher antimicrobial activity than drug alone 
and enhanced the susceptibility of P. aeruginosa from highly resis-
tant to gentamicin (MIC>16 mg/L) to either intermediate (MIC?8 
mg/L) or highly susceptible (MIC?4 mg/L) for the non-mucoid and 
mucoid strains of Pseudomonas respectively. The mechanism of 
enhanced activity due to the protection of the drug against enzy-
matic degradation, and ease of diffusion across the bacterial enve-
lope [183, 184]. 
 Turos et al. [185] evaluated the activity of penicillin encapsu-
lated within polyacrylate nanoparticles, prepared by free radical 
emulsion polymerization, against resistant strains of S.aureus. Mi-
crobiological assays indicated that the antimicrobial properties of 
nanoparticle-encapsulated penicillin were retained, whilst free peni-
cillin completely lost activity in the presence of penicillinase [184-
186]. 
 CF sputum being rich in polyanionic components, namely 
mucin, DNA, F-actin, lipopolysaccharides and lipoteichoic acid has 
been shown to reduce the antimicrobial properties of the cationic 
antibiotics polymyxin and tobramycin, due to formation of an elec-
trostatic-attraction complex, hampering complete eradication of the 
bacteria [99, 187, 188]. Encapsulation of these antibiotics in 
liposomes reduces formation of the electrostatic complex 100-fold, 
giving a 4-fold improved inhibition of P. aeruginosa colonies, sug-
gesting a potential application in eradication of chronic lung infec-
tions associated with CF [184, 187]. 
 Co-encapsulation of antimicrobial substances, such as metals 
with antibiotics in liposomes not only reduces the toxicity issues 
associated with metals on human cells but has also improved the 
activity of the co-encapsulated antibiotic [184, 189-194]. Halwani 
et al. [189] studied the effect of co-encapsulating of bismuth-
ethanedithiol and tobramycin (BiEDT-TOB) in DSPC: Chol 
liposomes on highly resistant strains of P. aeruginosa PA-48913. 
MIC values for liposomal BiEDT-TOB were 0.25 mg/L compared 
to 1024 mg/L for non-liposomal drug, which could serve as a new 
strategy for enhancing the antibacterial properties of tobramycin 
against resistant bacteria [189]. Halwani et al. [190] have also re-
ported the activity of DPPC: DMPG co-encapsulated gallium with 
gentamicin (Ga-GEN) liposomes against highly resistant strains of 
P. aeruginosa PA-48913. Liposomal Ga-GEN formulations com-
pletely eradicated the bacterial isolates growing in planktonic and 
biofilm communities at a concentration as low as 0.94 mg/L. They 
also interfered with the release of virulent factors, alginate and 
biofilm [184, 190, 192].  
7.2. Controlled Release 
 Antimicrobial therapy is hampered by the short availability of 
drug at the target site, potentially limiting treatment outcomes. Cur-
Table 7. Nanomicelles in literature for delivery of antimicrobials for treatment of pulmonary infections. 
POLYMER/ LIPID ANTIMICROBIAL MICROORGANISM ADVANTAGES 
Depolymerized chitosan-
stearic acid 
Nebulization 
Amphotericin B 
Antifungal 
Candida albicans, Aspergillus 
niger, Aspergillus fumigatus, As-
pergillus flavus Cryptococcus 
neoformans 
Similar efficacy against all the different fungi 
Retention of encapsulation of amphotericin B after 
nebulization indicating no effect on the physical proper-
ties of the micelles using a jet nebulizer [172] 
Branched polyethyle-
neimine-Stearic acid lipo-
polymer 
Dry powder inhalation 
Rifampicin 
Antimycobacterial 
Mycobacterium smegmatis Higher uptake and internalization of the cationic 
nanomicelles encapsulating rifampicin into phagosomal 
compartments of the alveolar macrophage cells THP-1 
due to proton-sponge effect was observed [173] 
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rently for chronic pulmonary infections, high-doses and frequent 
parenteral administration are necessary to achieve the pulmonary 
sputum concentrations required to eradicate the chronic colonies of 
biofilm-associated bacteria [195-197]. However, protracted and 
recurrent administration of high dose antibiotics is associated with 
antibiotic resistance [197-199]. Inhaled antibiotics also face consid-
erable challenges as they are rapidly cleared from the lungs by natu-
ral clearance mechanisms, namely exhalation for small particles, 
phagocytosis by macrophage and dendritic cells, mucociliary clear-
ance, enzyme degradation etc. This may lead to antibiotic exposure 
at sub-inhibitory levels, leading to incomplete eradication of bacte-
rial colonies embedded in the protective layers of sputum and 
biofilms, leading to higher incidences of antibiotic resistance [98].  
 A logical approach to enhance the delivery of antibiotics for 
treating chronic infections, by increasing their residence time, is to 
load them into appropriately sized carriers which could serve to 
deliver the drug to the site of infection. However, chronic admini-
stration of the carrier may lead to their accumulation in the airways. 
Despite the phospholipids used in the preparation of liposomes 
sometimes being endogenous to the lungs; their repeated admini-
stration can lead to cumulative doses of lipids in the lungs greater 
than the original surfactant pool, resulting in adverse effects, such 
as phospholipidosis [130, 200, 201]. Hence, excipients should be 
minimised, with nanocarriers designed to deliver antimicrobials 
encapsulated in controlled/sustained/extended release vesicles 
which release drug over extended periods, maintaining therapeutic 
levels in the vicinity of the biofilm, improving patient compliance 
whilst reducing chances for development of resistance [98, 197].  
 Although a number of research articles have been published on 
the controlled release of antibiotics given systemically or as post-
operative implants, few reports are associated with controlled re-
lease of antibiotics following pulmonary delivery [130, 202-204]. 
One such study used the encapsulation of nafcillin and levofloxacin 
in PLGA nanoparticles coated with calcium phosphate, to achieve 
controlled release of the antibiotics. The nanoparticles showed sus-
tained release for 4-6 weeks and inhibited biofilm formation with 
complete deterioration of S.aureus biofilms over a 7 day period 
[205]. 
 Another study demonstrated the anti-microbial property of gen-
tamicin encapsulated in PLGA nanoparticles. In-vitro efficacy of 
the PLGA encapsulated gentamicin against P. aeruginosa biofilm 
was superior to free drug, due to achievement of a sustained level of 
gentamicin in the biofilm. Moreover, peritoneal injection in murine 
infection models showed the effective clearance of bacteria and an 
enhanced anti-biofilm effect by PLGA encapsulated gentamicin 
after 96 h, compared to free gentamicin. Empty PLGA nanoparti-
cles did not demonstrate any antimicrobial effect against P. aerugi-
nosa [184, 206]. 
 Cheow and co-workers have illustrated the importance of anti-
biotic release profiles on the anti-bacterial activity against biofilm-
associated E.coli. Two nanoparticle systems: an extended (slow) 
release and a biphasic system with an initial burst release and sub-
sequent slow release, encapsulating the hydrophilic antibiotic 
levofloxacin were prepared, using either poly(caprolactone) (PCL) 
or PLGA polymers. Nanoparticles were prepared using two differ-
ent methods, namely nanoprecipitation and emulsification-solvent 
evaporation. It was observed that with the extended-release 
nanoparticles encapsulating levofloxacin, the concentration of anti-
biotic was above the MBIC value at all times, but was unsuccessful 
in eradicating biofilm-associated bacterial cells. A higher antibiotic 
resistance was prevalent in the biofilm cells with lower initial anti-
biotic concentration, which was then passed onto the progeny lead-
ing to ineffective eradication. For the biphasic-release nanoparticu-
late system was better in decelerating occurrence of biofilm forma-
tion, indicating the importance of a high initial local concentration, 
then an extended release to maintain the concentration of drug in 
the biofilm above the MBIC at all times. However, over a 6-day 
period both nanoparticulate antibiotic preparations were unable to 
prevent biofilm growth when a single dose was administered. Nev-
ertheless a related study by the same group demonstrated the effect 
of release profile of hydrophobic ciprofloxacin encapsulated in 
PLGA and PCL nanoparticles, prepared by the emulsion-solvent 
evaporation method. PLGA encapsulated ciprofloxacin, over a 5-
day period, showed successful inhibition of the biofilm- associated 
bacteria even at concentration as low as 1/16th of the MBIC, indi-
cating this to be a highly effective formulation for eradication of 
biofilm-associated E.coli [184, 207-209]. These studies highlight in 
considering the susceptibility of chronic bacterial infections to 
nanocarrier formulations of antimicrobials, the importance of the 
formulation parameters, such as drug properties, choice of polymer, 
method of preparation of nanoparticles, release profile, etc.  
7.3. Non-Specific Targeting 
 Nanoparticles can be targeted passively by selective extravasa-
tion at the site of infection, due to the increased porosity of blood 
vessel induced by increased inflammatory factors [53]. Eradication 
of intracellular organisms presents severe challenges as therapeutic 
concentrations of antimicrobials in intracellular compartments are 
difficult to achieve due to their limited penetration capacity [210, 
211]. Thus, many antibiotics, such as ?-lactam and aminoglycoside 
antibiotics show low concentrations in intracellular compartments 
due to poor penetration and acidic and enzymatic degradation. 
However, water-soluble quinolone and macrolide antibiotics, such 
as clindamycin, levofloxacin, etc. attain higher intracellular concen-
trations as opposed to extracellular concentrations [210-212]. My-
cobacterium tuberculosis binds to and internalizes in the alveolar 
macrophages as a survival mechanism, and hence is very difficult to 
eradicate completely. A study of liposome- encapsulated clo-
fazimine against TB showed that liposomal formulations were 
much more effective in being taken up naturally by the macro-
phages, where the infection prevails, improving treatment outcomes 
and reducing off-target toxicity of the anti-tubercular drug in-vitro 
and in-vivo [213, 214]. Liposomal clofazimine was more effective 
in treatment of acute and chronic murine TB, giving a bactericidal 
effect with no re-emergence of Mycobacterium tuberculosis infec-
tion in mice [213, 214]. Another study by Stoops et al showed that 
lipids have the tendency to strip off the waxy trehalose dimycolate 
armour of Mycobacterium making it more susceptible to anti-
tubercular drugs hence improving their efficacy [215]. 
 The fusogenic property of liposomes makes them an attractive 
approach for delivering antibiotics directly to cells, due to their 
potential to fuse with phospholipid cell membranes. The fluidity of 
the liposomes can be achieved by lowering the phase transition 
temperature, by incorporation of components of the inactivated 
Sendai virus envelope, using lipids which have the phosphatidyle-
thanolamine moiety, lipids with double bonds and/or asymmetry in 
acyl chain, or by addition of cholesterol [184, 216-220]. Antibiotics 
enter Gram-negative bacteria by two routes: hydrophobic drugs 
enter by passive transport via the lipopolysaccharide and protein-
rich outer membrane; whereas hydrophilic drugs enter through the 
outer membrane water-filled porin channels. A reduction in antibi-
otic susceptibility of resistant strains of bacteria has been reported 
due to acquisition of genetic factors which lead to changes in the 
bacterial outer membrane porin channels, which strongly impacts 
the influx of antibiotics and hence bacterial susceptibility [219, 
221-224]. Nicolosi et al. have studied the antimicrobial sensitivity 
of the glycopeptide antibiotic vancomycin against ten wild strains 
of Gram-negative bacteria using vancomycin encapsulated in fu-
sogenic: (DPPC: DOPE: cholesterol hemisuccinate) and non-
fusogenic liposomes (DPPC: cholesterol) as well as free drug. A 
significant reduction in MIC was observed for the vancomycin 
encapsulated in fusogenic liposomes for all the strains of bacteria 
tested, with an MIC as low as 6 mg/L for strains of E.coli and 
Acinetobacter baumannii, compared to vancomycin encapsulated 
non-fusogenic liposomes and free vancomycin which both had an 
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MIC of 512 mg/L. This was due to the fusogenic phospholipid 
vesicles fusing with the E.coli bacterial membrane, as confirmed by 
scanning and transmission electron micrographs [219, 225].  
 Beaulac et al. showed that bacterial susceptibility to antibiotics 
encapsulated in liposomes is largely determined by the fluidity of 
the liposomal phospholipid bilayer. In vivo studies were performed 
on the lungs of rats which were chronically infected intratracheally 
with the mucoid variant of Pseudomonas aeruginosa (PA 508), 
which is the most common opportunistic organism accelerating 
chronic pulmonary infection in cystic fibrosis patients, and in non-
cystic fibrosis bronchiectasis patients. A significantly improved 
antimicrobial susceptibility was evidenced by a dramatic reduction 
in mucoid bacterial load in the lungs (0-8 CFU/pair of lungs) for the 
tobramycin encapsulated in DPPC: DMPG liposomes called Flu-
idosomes™ which had a phase transition temperature (Tc) of 
29.5°C. Free tobramycin and tobramycin encapsulated in rigid 
DSPC: DMPC liposomes (Tc=42°C) showed much higher bacterial 
loads of 2x105-4.2x107 and 1.9x105-4.3 x106 CFU/pair of lungs 
respectively, with three doses of 600 ?g at 16 h intervals. Moreo-
ver, distribution studies after the last treatment of the liposomal 
formulation and the free antibiotic showed a high level ?27 ?g/mg 
in lung tissue, and 0.59-0.87 ?g/mg of tissue detected in the kidneys 
as opposed to 5.31 ?g/mg of kidney tissue for the free drug. This 
suggests that liposome encapsulated tobramycin would not only be 
beneficial for management of chronic pulmonary infection, but also 
in reducing the systemic side effects and toxicity associated with 
conventional antibiotics. Moreover, studies performed with the 
DPPC: DMPG liposomes (Tc=33°C) at a lower dose regimen of 
two tobramycin treatments of 240 ?g at 16 h intervals showed a 
bacterial load of. 0-3 CFU/pair of lungs comparable with the high-
dose treatments, whereas free tobramycin showed a significantly 
higher bacterial load of 1.6x105-1.5x106 CFU/pair of lungs [184, 
226]. 
 Fluidosomes™-Tobramycin is being developed by Axentis 
Pharma (Switzerland) and has shown good safety and efficacy pro-
files in pre-clinical and Phase II clinical trials when compared to the 
present available marketed treatments for management of chronic 
infection caused by Burkholderia cepacia pathogens associated 
with cystic fibrosis. 
 Non-specific approaches to targeting suffer from the drawbacks 
of non-specific drug delivery and uptake, hence selectively target-
ing to the site of infection may represent an attractive approach to 
increase uptake, to achieve higher doses to eradicate bacteria at the 
appropriate site, allow a reduction in dose and potentially reduce 
the potential for antimicrobial resistance.  
7.4. Specific Targeting 
Biofilm Targeting 
 Understanding the generation of biofilms at the genetic and 
molecular levels has informed the development of drug delivery 
systems which may help in overcoming this physical barrier to 
effective antimicrobial therapy, and help in better elimination of 
chronic bacterial infections associated with biofilms.  
Li et al. demonstrated the influence of nanoparticle surface 
properties with respect to both surface charge and hydrophobic-
ity/hydrophilicity on the penetration of biofilms secreted by E. coli 
strain DH5a. Quantum dots (QD) with different functional head 
groups were synthesized by surface modification to obtain neutral, 
i.e. poly(ethylene glycol)-appended DHLA-QD, negatively-charged 
COOH-QD and positively-charged QD which were further de-
signed to be hydrophobic, i.e. dimethylhexyl ammonium terminus 
(Hexyl-QD) or hydrophilic i.e. trimethylammonium terminus 
(TTMA-QD). 3-D projection of images obtained from a z-stack 
using a confocal laser scanning microscope clearly showed that the 
neutral (PEG-QD) and negative-charged COOH-QD did not adhere 
or penetrate into the EPS of the biofilm, demonstrated by the ab-
sence of green fluorescence indicative of the QD amidst the red, 
fluorescing bacterial cells. Both the hydrophobic and hydrophilic 
positively-charged QDs showed a high intensity of green fluores-
cence which did not disappear on washing the biofilms with PBS, 
whilst quantification of penetration profiles of the positively 
charged QDs showed they had travelled through the biofilm to a 
depth of 7.2 ?m. Moreover, co-localization of the hydrophobic 
Hexyl-QDs with the bacterial cells indicated greater uptake of these 
compared to the hydrophilic TTMA-QDs which primarily localized 
in the EPS of the biofilm. Hence this study has shown the impor-
tance of charge and surface properties, whereby a hydrophobic 
surface of nanoparticles could be engineered to deliver antibiotics 
for eradication of chronic intracellular pathogens, whereas a hydro-
philic surface modification could serve to target enzymes and other 
biofilm-dissolving drugs, for dispersion of biofilms [227]. 
 An attractive approach in disassembling the EPS matrix of bac-
terial biofilms, and hence enhancing antibiotic therapy was studied 
by Baelo et al. Ciprofloxacin was loaded into PLGA nanoparticles, 
with and without a coating of DNAse enzyme. This enzyme has 
been found to be very effective in disrupting the integrity and vis-
coelastic nature of the DNA-rich EPS of biofilms, and greatly im-
proves diffusion through it [228, 229]. Ciprofloxacin was encapsu-
lated in PLGA coated with DNAse by means of covalent linkage 
using poly-lysine on the surface of PLGA nanoparticles. These 
particles had improved mobility in Pseudomonas aeruginosa 
biofilms in both static and dynamic conditions, providing a plat-
form for treatment of biofilm-associated bacteria with biofilm dis-
assembling and anti-bacterial agents [229]. 
Sputum Targeting  
 The CFTR gene defect discovered in 1989 has not yet resulted 
in a cure for CF. Major treatment failures have been attributed to 
the hyper-viscoelastic mucus ‘sputum’ due to inefficient transport 
of therapeutics. This pathological complication also affects treat-
ment of other etiological diseases, such as COPD, chronic bron-
chiectasis and asthma. Numerous studies have been conducted on 
the sputum expectorated from CF patients to understand the nature 
of the matrix microstructure, mesh spacing and its components to 
aid in delivering antibiotics and gene vectors through this obstacle. 
Suk et al. have shown that densely packed low molecular weight 
PEG imparted ‘muco-inertness’ to the surface of polystyrene (PS) 
nanoparticles of different sizes. Transport of these nanoparticles 
through CF sputum, studied using multiple particle-tracking analy-
sis, showed that the uncoated PS nanoparticles with a charge on the 
surface due to a terminal amine group had a strongly hindered 
transport, whereas similarly sized nanoparticles with a muco-inert 
surface which showed greater movement in time-lapse studies. This 
was attributed to possible polyvalent adhesion interactions between 
the hydrophobic mucin fibres and hydrophobic core of PS nanopar-
ticles, and also electrostatic interactions of the positively-charged 
nanoparticles with sputum components, such as DNA, F-actin etc. 
all of which were masked when particles were densely coated with 
hydrophilic, uncharged PEG molecules [229]. A further study has 
been conducted by the same group, in which the transport of biode-
gradable, di-block copolymers prepared from sebacic acid and 
methoxy-PEG were compared to latex particles in undiluted sputum 
expectorated from CF patients. It was seen that the biodegradable 
muco-inert nanoparticles had a mean square displacement 50-fold 
greater compared to uncoated latex particles, and a Fick diffusion 
model confirmed the penetration of the muco-inert PSA-PEG 
nanoparticles to be 31% in 30 mins compared to the unmodified 
particles which showed strong immobilization and penetration of 
only 0.6% in CF sputum [230]. These studies demonstrate the im-
portance of nanoparticle properties such as surface charge, 
hydrophobicity, molecular weight, size, etc. on the transport of 
particles and the encapsulated drug through the sputum [229, 230]. 
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Macrophage Targeting  
 As highlighted above, alveolar macrophages play a major role 
in combating infections. However in chronic infections, bacteria 
and other organisms take these over, locating themselves in the 
protective environment where they multiply and become difficult to 
eradicate with routine antibiotics. To eradicate these intracellular 
infections, directly targeting to the macrophages could be a highly 
effective strategy. Much research has been performed to study the 
potential of PLGA microparticles and nanoparticles to target the 
alveolar macrophages, as they may remain membrane bound onto 
the alveolar macrophages for up to 2 weeks [231-239]. Makino et 
al. showed the phagocytic uptake of rifampicin encapsulated in 
PLGA nanoparticles. 19-times higher uptake of rifampicin by the 
macrophage cells in-vitro was found for PLGA-encapsulated rifam-
picin formulation compared to free drug in solution [236]. A similar 
study exploring the reasons for an increased uptake of PLGA 
nanoparticles into macrophage cells, concluded that 90% of PLGA 
nanoparticles encapsulating rifampicin were taken up and remained 
membrane bound onto the low pH hydrolase rich regions of the 
phago-lysosomes for 13 days, as shown by fluorescence and im-
mune-electron microscopy, from where rifampicin is released over 
time. Further studies have confirmed that this formulation system 
was more efficient in eradication of mycobacterium bovis infected 
macrophage RAW cells compared to free rifampicin at the same 
concentration. Actively targeting nanoparticles to alveolar macro-
phages has been extensively investigated for treatment of various 
infections associated with tuberculosis, visceral leishmaniasis, ar-
thritis, etc. [240-242]. Gelatin nanoparticles encapsulating isoniazid 
with and without mannose conjugated to the surface of nanoparti-
cles, required for selective delivery to macrophages, have been 
studied. Macrophage-uptake studies showed that mannosylated 
nanoparticles were taken up preferentially into macrophages com-
pared to non-mannosylated nanoparticles. The anti-tubercular activ-
ity, studied by inducing TB infection in BALB/C mice, showed 
much lower CFU/ml of spleen when the mice were treated with 
mannosylated gelatin nanoparticles encapsulating isoniazid, com-
pared to non-mannosylated nanoparticles encapsulating isoniazid 
and free isoniazid. This suggests the macrophage uptake of the drug 
encapsulated in nanoparticles is an important pre-requisite for 
treatment of intracellular infections. Similar results have been ob-
served by others, studying conjugation of mannose onto SLNs, 
polypropyleneimine dendrimers, etc. [243-245]. 
7.5. Higher Uptake and Retention in Lung Tissue 
Antimicrobial lung concentrations are of crucial importance, as 
a drug concentration above the MIC and MBIC are required to 
achieve successful eradication of the infecting pathogens. 
Liposome-encapsulated amphotericin B has been long been suc-
cessfully marketed under the name AmBisome for intravenous 
infusion for the treatment of severe systemic and deep mycosis in 
the lungs. Several studies have been performed delivering these 
liposomes and other lipid-based systems via nebulization directly to 
the pulmonary tract to achieve high local concentrations and reduce 
undesirable systemic effects [246-248]. One such study has high-
lighted the beneficial effects of nebulized amphotericin B encapsu-
lated in liposomes, compared to Fungizone (sodium deoxycholate 
complex) using a SPAG-2 nebulizer. AmBisome showed an eight-
time higher concentration in the lungs (207 ?g/mg lung tissue) than 
Fungizone (24.4 ?g/mg lung tissue) using in-vivo in murine models 
infected with Aspergillus fumigatus. Also, with a medium infection 
load of 107 CFU/g of tissue, AmBisome produced nearly com-
pletely eradicate from the lungs (mean CFU/g of lung tissue=0.54); 
however, Fungizone showed no improvement in eradication com-
pared to the control group (mean CFU/g of lung tissue=3.31 for 
Fungizone and 5.30 for control). This demonstrates the importance 
of higher lung retention achieved with nanotechnology- based vesi-
cles and their consequent beneficial effects on eradication of bacte-
ria. Clinical trials are on-going for nebulized AmBisome (AM-
BINEB) in prophylaxis of Invasive Pulmonary Aspergillosis in 
patients with Acute Myeloid Leukaemia and Allogeneic Haema-
topoietic Progenitor Cell Transplantation. Further clinical trials are 
being conducted following completion of Phase II studies of pro-
phylactic nebulization of amphotericin B-lipid complex (Albecet®) 
in paediatric patients with acute leukaemia [246-248]. 
8. DISADVANTAGES OF NANO-ANTIMICROBIALS 
8.1. Formulation Drawbacks  
 Nanoparticles present many challenges, potentially limiting 
their progress onto the market. Key drawbacks are (1) Scale up and 
transitional development from the laboratory bench to industrial 
production is a challenge due to differences in the properties of 
nanoparticles compared to their bulk counterparts. Smaller sizes 
and commensurate large surface area can lead to high chances of 
aggregation, hindering physical handling at an industrial level 
[249]. (2) Low drug encapsulation is a major limitation, and is often 
dependent on aqueous/lipid solubility, as exemplified by a drug’s 
logP. (3) Stability of nanocarrier-drug formulation may be prob-
lematic, for instance leakage of drug on storage, changes in size and 
surface properties and, particle-particle interaction and aggregation 
(4) Stability of formulation to aerosolization processes, especially 
by nebulization of nanocarriers dispersed in liquid, which may re-
sult in particle rupture and drug loss and consequently unpredict-
able deposition patterns within the airways.  
8.2. Toxicity of Nanoparticles to the Lung  
 With the advent of nanoparticle drug delivery in pharmaceuti-
cal, biomedicine and cosmeceutical areas, the field of nanotoxicol-
ogy has emerged to investigate potential adverse reaction to 
nanoparticles [53, 250]. Nanomaterial structures, due to their very 
small size and large surface area have a potential to be more toxic 
than conventionally sized bulk samples of the same materials. This 
is due to their deeper lung penetrations, large surface/mass ratios, 
aggregation capabilities and low water solubility. It has been seen 
that human alveolar macrophages are not capable of removing 
nanoparticles of size 70 nm and less, leading to their deep lung 
access and entrance into bloodstream through the alveolar epithe-
lium, and causing evident inflammation in other organs. The aggre-
gation state is another important determinant. Aggregates of ul-
trafine carbon particles at concentrations of 1 ?g/ml and greater 
impair the phagocytic function of human alveolar macrophage. The 
large surface area/mass ratio enables these nanoparticles to undergo 
various reactions which result in toxicity and cause inflammation in 
animal models, whereas their counterpart larger particles have de-
monstrable safety. This is due to novel surface characteristics which 
may contribute to reactions like generation of reactive oxygen spe-
cies, i.e. free radical formation as shown for CuO and SiO2 
nanoparticles; interlukin-8 cytokine production evident following 
exposure to cobalt or TiO2 nanoparticles; increase in mRNA levels 
of inflammatory markers shown for by yttrium and zinc oxide 
nanoparticles. 
 To study toxicity, regulatory authorities require animal studies; 
however, in-vivo studies are conducted using oral, intraperitoneal or 
dermal routes which do not completely portray inhalation effects. 
In-vitro methods have been developed to study toxic effects on 
airway cells (Calu-3 human cell line), alveolar epithelium (A549-
human cell line) or tissues. These are quicker, simpler and less ex-
pensive than in-vivo tests. However, they do not completely take in 
account lung characteristics, such as microenvironments and inhala-
tion effects [250]. 
CONCLUSION 
 Huge research efforts are being made to overcome the draw-
backs of conventional antimicrobials used to treat lower respiratory 
tract infections, which are one of the leading causes of death 
worldwide. In light of the increased incidence of multi-drug resis-
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tance to conventional antimicrobials, there is an urgent need for 
better treatment modalities. Moreover, the high rates of side effects 
with prolonged oral and parenteral delivery of current antimicrobi-
als and low drug availability at the pulmonary site leads to insuffi-
cient levels of drug in the sputum for eradication of infections. This 
is one of the greatest reasons for failure of current treatments for 
pulmonary infections. Direct delivery of antimicrobials, by inhala-
tion, to the pulmonary tract could help in not only reducing side 
effects, but also in lowering the dose required to eradicate the bac-
terial load and reduce the potential for resistance and recurrence of 
infection. Furthermore, targeting therapeutic agents to the intracel-
lular pathogens, or to pathogens embedded within protective cover-
ings like sputum and biofilms, may be achieved by utilizing one of 
the ever-growing nanotechnology platforms for encapsulation of 
antimicrobials into nanosized vesicles, such as liposomes, polym-
eric nanoparticles or micelles. Development of nanosized drug de-
livery systems encapsulating antimicrobial drugs capable of being 
directly administered to the lungs could result in breakthroughs in 
the therapy of notoriously difficult to treat pulmonary infections. 
LIST OF ABBREVIATIONS 
BAL = Broncho-alveolar lavage 
CAP = Community acquired pneumonia 
CB = Chronic bronchitis 
CF = Cystic fibrosis 
CFU = Colony forming units 
CHOL = Cholesterol 
COPD = Chronic obstructive pulmonary disease 
DCP = Dicetyl phosphate 
DMPC = 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
DMPG = 1,2-Dimyristoyl-sn-glycero-3-phosphoglycerol 
DOPE = 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine 
DPPC = 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
DPI = Dry powder inhaler 
DSPC = 1,2-dioctadecanoyl-sn-glycero-3-phosphocholine 
DSPG = 1,2-Distearoyl-sn-glycero-3-phosphoglycerol 
EGG PC = Egg phosphatidylcholine 
EPS = Extracellular polymeric substance 
GSD = Geometric standard deviation 
HLB = Hydrophilic-lipophilic balance 
HSPC = Hydrogenated soybean phosphatidylcholine 
LPNAPS = Large porous nanoparticle aggregates 
LPP = Large porous particle 
MAN = Mannose 
MBIC = Minimum biofilm inhibitory concentration 
MDR-TB = Multi-drug resistant tuberculosis 
MIC = Minimum inhibitory concentration 
MMAD = Mass median aerodynamic diameter 
PCL = Poly-epsilon-caprolactone 
PLGA = Poly(lactic-co-glycolic acid) 
pMDI = Pressurized metered dose inhaler 
QD = Quantum dot 
TB = Tuberculosis 
TDR-TB = Totally drug resistant 
VAP = Ventilator-associated pneumonia 
XDR-TB = Extensively drug resistant  
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